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ABSTRACT 
 
RNA-binding proteins control a variety of biological processes ranging from messenger 
RNA splicing to transport and translation.  These post-transcriptional events are critical for 
proper cell function.  One emerging class of proteins functions in several of these capacities.  
The VICKZ family of RNA-binding proteins is involved in translation control, mRNA 
localization and mRNA stability.   I have studied the Insulin-like Growth Factor-2 mRNA-
Binding Protein 1 (IGF2BP1/IMP-1/CRD-BP).  IMP-1 exhibits an oncofetal pattern of 
expression, where it is expressed in embryonic development and its expression is repressed 
shortly after birth.  However, the IMP-1 gene is reactivated in many different human cancers.  
Overexpression of IMP-1 leads to increased levels of proteins that promote tumor growth, 
metastasis, and resistance to anticancer drugs and is associated with a poor prognosis.  IMP-1 
enhances proliferation and migration of cancer cells by binding to and stabilizing mRNAs 
important in cancer, such as c-Myc.   Although the role of c-Myc in cancer has been well 
established, it has remained an elusive therapeutic target because of its role as a transcription 
factor in non-neoplastic proliferating cells.  Given its oncofetal pattern of expression, targeting 
IMP-1 presents a novel approach to targeting c-Myc.  To identify new chemical entities with 
therapeutic potential in IMP-1 positive cancer, we carried out a pilot screen using an in vitro 
fluorescence anisotropy microplate assay (FAMA) and found that this approach was robust and 
appropriate for high throughput screening.  We then carried out a high throughput screen of 
approximately 150,000 small molecules. Reported here is BTYNB, the first small molecule 
inhibitor of IMP-1, BTYNB decreases levels of IMP-1 target mRNAs, inhibits proliferation of 
IMP-1 positive cancer cells, and functions through the unique mechanism of decreasing 
oncogene mRNA stability.  We believe that BTYNB not only can be developed as a potential 
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therapeutic agent, but also serves as a useful molecular tool, with which we can probe the actions 
of IMP-1 in cancer cells.  In addition to identifying and characterizing the first small molecule 
inhibitor of IMP-1, we were also interested in identifying novel molecular targets of IMP-1.  
Using in silico analysis of publically available microarrays where IMP-1 was knocked down, we 
identified a panel of candidate target genes.  Using qRTPCR and Western blot analysis, we then 
confirmed whether or not the mRNAs of candidate genes were decreased with IMP-1 
knockdown and identified Protein Kinase C  (PKC) as a new molecular target of IMP-1.   
Overall, this work has led to the identification and characterization of the first small 
molecule inhibitor of IMP-1 and has demonstrated that despite the fact that studies of the role of 
IMP-1 in cancer are rapidly expanding, there still remain novel molecular targets, such as PKC, 
which may play critical roles in IMP-1 action in cancer cells.   
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CHAPTER 1 
BACKGROUND 
 
RNA-Binding Proteins 
Post-transcriptional modifications of mRNA transcripts at the 5’ and 3’ ends stabilize and protect 
the mRNAs from nucleolytic attack by degradative enzymes.  RNA-binding proteins also play a 
critical role in protecting mRNAs, by binding to and protecting mRNAs from nucleases (1).  
Although RNA-binding proteins are known to play a role in regulating translation, little is known 
about the specific interactions that allow for this regulation (2). There is extensive RNA-binding 
protein involvement in the posttranscriptional processing of mRNAs, whereby RNA-binding 
proteins recognize specific features in the mRNAs and bind nascent transcripts at specific times 
during the processing of the mRNA (2).  There are a variety of motifs that the RNA-binding 
proteins use to recognize and bind to RNA. Their ability to regulate gene expression and mRNA 
levels means that RNA binding protein overexpression has been identified in many diseases, 
including cancer (3,4).  An example of an mRNA-binding protein that has emerged as a key 
regulator of oncogenes is IGF2BP1 (Insulin-like Growth Factor 2 mRNA Binding Protein 1), 
also known as IMP-1.   
 
Insulin Like Growth Factor 2 mRNA Binding Protein (IGF2BP1/IMP-1) Orthologs 
IGF2BP1, also known as IMP-1 (human) and Coding Region Determinant-Binding Protein 
(CRD-BP; mouse) belongs to a highly conserved family of RNA binding proteins called VICKZ 
(Vg1RBP/Vera, IMP-1,2,3, CRD-BP, KOC, ZBP-1) (5,6). Figure 1.1 shows the amino acid 
alignment of heterogeneous nuclear Ribonucleoproteins-K-homology (KH) domains for IMP-1 
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and related proteins. Discussed in more detail in a later section, the KH domains of IMP-1 are 
necessary for binding to appropriate RNA targets.  Interestingly, there is >98% structural 
similarity between human IMP-1 and mouse CRD-BP.  The strong evolutionary conservation of 
this protein family highlights the biological importance of their many proposed functions. 
 
Figure 1.1 Alignment of KH RNA-binding domains of IMP-1 and related proteins. KH 
domain consensus sequence are shown in bold and by asterisks below the alignment. 
GenBank accession numbers are as follows: mCRDBP, AF061569; hCRDBP EST, 
AA196976/AA196977; chZBP1, AF026527; hKOC, U97188; xTFB3, AF042353; Vg1 
RBP/Vera, AF064633 and AF055923, respectively.  Adapted from Doyle et al, NAR 1998. 
 
Other orthologous or paralogous members of the IGF2BP protein family include IMP2 (human), 
IMP3 (human), ZBP1 (chicken), and Vg1-RBP/Vera (Xenopus). The variety of names that have 
been attributed to the same protein illustrates the fact that investigators from various fields have 
identified distinct activities for the same molecule (Table 1.1).   
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Table 1.1 The VICKZ family of RNA Binding Proteins 
Binding Protein RNA Function Reference 
Vg1RBP Vg1 mRNA 
transport/translation 
(7-9) 
ZBP-1 β-actin  
 
mRNA transport (10-12) 
CRD-BP c-Myc Inhibition of CRD-
dependent mRNA 
decay 
(13-17) 
IMP-1 MDR1 Inhibition of CRD-
dependent mRNA 
decay 
(18) 
IMP-1 BTRC Inhibition of miR-
dependent mRNA 
decay 
(19,20) 
IMP-1/3 CD44 Inhibition of mRNA 
decay 
(21) 
IMP-1 KRAS Inhibition of mRNA 
decay 
(22) 
IMP1, CRD-BP, and ZBP1 only differ by 17 amino acids and are considered the same protein. 
 
 
 
The Xenopus Vgl RNA-binding protein (VglRBP/Vera) localizes Vgl mRNA within the 
cell during Xenopus oogenesis (23). VglRBP recognizes the specific 3’UTR vegetal localization 
element (VLE) and localizes the mRNA to the vegetal cortex; therefore, Xenopus VglRBP is key 
in cellular developmental and differentiation (23). Importantly, IMP-1/CRD-BP/IGF2BP1 plays 
a critical role in mRNA decay (13,18,20,24,25), translation (13,26) and localization  (27,28) and 
has been show to bind to a number of mRNA targets that are implicated in cancer (6).   IMP-1 
binds to the 5’-UTR of IGF-II mRNA, inhibiting the translation of the transcript and transgenic 
mice that overexpress IMP-1 have shown increases in IGF-II protein levels, which was 
accompanied by the induction of mammary tumors (17,29).  IMP-1 binds to the 3’-UTR of H19 
mRNA and the coding region stability determinant of c-Myc mRNA, promoting cell 
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proliferation and tumorigenesis (6).  KOC RNA-binding protein, also known as IMP-3, exhibits 
an oncofetal pattern of expression where it is nearly absent from normal non-neoplastic cells, and 
found in melanomas, gastric adenocarcinoma, ovarian and pancreatic cancer  (30-33).  These 
results suggest that the IGF2BP protein family play extensive roles in the regulation of many 
genes, many that lead to the development of various cancers (6).   
 
IMP-1 Structure and Action 
Human Insulin Like Growth Factor 2 mRNA Binding Protein 1 (IGF2BP1/IMP-1) is a member 
of the highly conserved VICKZ RNA-binding protein family (5).  IMP-1 is a 577 amino acid 
protein which contains two N-terminal RNA recognition motifs (RRM) followed by four C-
terminal heterogeneous nuclear Ribonucleoproteins-K-homology (KH) domains (Fig. 1.2) (34-
36).  
       1              577 
N                  C 
 
 
Figure 1.2. Domain structure of IMP-1. The figure maps the known functional domains of 
IMP-1. 
 
To determine the importance of structural domains of ZBP-1, the ortholog of IMP-1 in chickens, 
in binding β-actin mRNA, researchers performed GST pull-down assays using  truncated 
versions of ZBP-1 (11).  Farina and co-workers found that full length ZBP-1 was able to bind to 
the zipcode region of β -actin mRNA with a Kd of 1-10 nM. However, the truncated versions 
containing only the RRM domains or only the KH1-KH2 domain, were unable to bind the 
zipcode region of β –actin mRNA (11).  This, in addition to other experiments supported the 
RRM
2 
RRM
1 
KH1 KH2 KH3 KH4 
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conclusion that the KH3 and KH4 domains, but not the RRMs nor KH1 and KH2 domains, are 
important in binding the β -actin mRNA zipcode region.  A recent structural study showed that 
IMP-1 induces the RNA looping of target mRNA upon KH3 and KH4 domain recognition, 
suggesting the importance of the KH3 and KH4 domains in binding (12).  Additionally, this 
study solved the crystal structure of the KH3-KH4 domain for IMP-1, and it was found that both 
the KH3 and KH4 domains adopted the β1α1α2β2β2α3 orientation with the highly conserved 
flexible G-X-X-G linker connecting the α1 and α2 helices, suggesting the importance of KH3 and 
KH4 in binding IMP-1 target mRNAs (12).   
IMP-1 traffics between the cytoplasm and nucleus via two nuclear export signals (NES), 
which  are located in the KH2 and KH4 domains (37).  It is hypothesized that IMP-1 binds to 
target mRNAs within the nucleus and that the subsequent IMP-1 containing messenger 
ribonucleoprotein (mRNP) complex is exported from the nucleus to distinct cytosol regions. For 
example, in motile cells, IMP-1 containing mRNPs localize β-actin mRNA to the cell periphery. 
IMP-1 mRNP granules have recently been purified from HEK-293 cells and these 100-300 nm 
particles contain 10-30 mRNA transcripts (38).   Approximately 300 distinct mRNA transcripts 
were found in IMP-1 mRNPs in this cell line, representing approximately 3% of the mRNA 
transcriptome.  
IMP-1 was initially identified for it its ability to protect c-Myc mRNA from degradation 
(24,39).   The mRNA of c-Myc is destabilized via rare codon usage at the start of the coding 
region stability determinant (CRD) (34,40), which induces translational stalling and subsequent 
cleavage of the transcript at the CRD.   Other studies show that IMP-1 can directly protect c-Myc 
mRNA from degradation by a mammalian endoribonuclease (18).  This data suggests IMP-1 
may also function within polysomes to protect c-Myc mRNA from cleavage during times when 
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translation is stalled. Earlier studies indicated that that RNAi knockdown of IMP-1 caused a 
significant portion of c-Myc mRNA to shift to the polysome fraction where it was degraded due 
to low availability of tRNAs  fitting the rare codon requirements of the CRD (13). This suggests 
IMP-1 may work in part by limiting the supply of mRNA available to the actively translating 
polysome fraction. While the precise mechanism by which IMP-1 stabilizes c-Myc mRNA 
remains obscure, several studies provide in vivo evidence that IMP-1 controls the half-life of c-
Myc mRNA (13,17,41). 
In addition to c-Myc, IMP-1 binds to other oncogenic mRNAs that promote 
tumorigenesis.  IMP-1 binds to the coding region of  βTrCP1 mRNA and over-expression of 
IMP-1 leads to stabilized βTrCP1 mRNA and elevated βTrCP1protein levels, resulting in 
suppression of apoptosis in colorectal cancer cells (19).   Also in colorectal cancer cells, IMP-1 
binds to and stabilizes GLI1 mRNA leading to elevated GLI1 protein, transcriptional activation, 
and proliferation (42).  IMP-1 has a high affinity for the coding region of multidrug resistance 
protein 1/ P-Glycoprotein (MDR1) mRNA (18).  Consistent with the view that IMP-1 protects 
MDR1 mRNA from degradation, down-regulation of IMP-1 reduces MDR1 levels and re-
sensitizes cancer cells to chemotherapy drugs (43).   In addition to binding to the coding region 
of oncogenic transcripts, IMP-1 binds to the 3’-untranslated region (UTR) of mRNAs, a classical 
site for RNA-binding protein regulation.  For example, IMP-1 binds to the coding region and 3’-
UTR of K-Ras mRNA and its overexpression led to increases in c-Myc and K-Ras expression as 
well as to proliferation of colon cancer cells (22).   The 3’-UTR of MITF mRNA is also a 
binding site for IMP-1 and this interaction is critical for protecting the MITF transcript from 
degradation by micro RNA 340 (miR-340), a mechanism believed to be important for cell 
proliferation in malignant melanomas (44,45).    IMP-1 also binds with high affinity to sites in 
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the 3’-UTR of CD44 mRNA, and knockdown of IMP-1 reduces stability of CD44 mRNA, 
decreases CD44 protein, and reduces cellular adhesion and invadopodia (21).  Importantly, these 
findings support the role of IMP-1 in mediating cancer cell metastasis and invasion.  As 
summarized in Figure 1.3, IMP-1 is a master regulator stabilizing a number of mRNAs whose 
protein products have been implicated in cancer through their ability to promote cell 
proliferation, metastases and tumor-enabling inflammation (6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Schematic representation of IMP-1 action (from Mahapatra L., et al 2013). 
 
Control of IMP-1 Expression 
Despite its emerging role in cancer, there is surprisingly little known about how IMP-1 
expression is regulated at the transcriptional level.  In studies in HEK293 cells, IMP-1 
transcription was proposed to be induced by β-catenin (CTNNB1) in a TCF-dependent manner.   
 8 
 
In turn, CTNNB1-induced activation of IMP-1 expression was proposed to promote IMP-1-
dependent stabilization of the BTRC and c-Myc mRNAs leading to elevated expression of both 
proteins (19).  Post-transcriptional control of mRNA fate is a major regulatory mechanism by 
which gene expression is controlled.  Studies from the Bartel lab found that differential lengths 
of the 3’ end of the IMP-1 transcript play a critical role in determining IMP-1 expression (46).  
Consistent with various in silico-predicted poly-adenylation sites in the approximately 7-kb-long 
3’-UTR of the transcript, at least three IMP-1 transcripts were observed in various tumor-derived 
cells and HEK293 cells, supporting the idea that  IMP-1 expression is modulated by alternative 
polyadenylation (APA).  Despite this exciting observation, the mechanism by which APA of 
IMP-1 is controlled has yet to be determined; however, it is probable that the 3’UTR shortening 
provides a potent escape route, preventing targeting by repressive microRNAs.  This appears to 
be preferentially observed for transcripts encoding oncogenic factors which are targeted by 
tumor-suppressive microRNAs like the let- 7 family, as demonstrated for IMP-1 (47).   Post-
transcriptional control of IMP-1 expression by microRNAs was suggested to modulate tumor cell 
fate. Downregulation of let-7 expression, frequently observed in aggressive tumor cells, was 
correlated with increased drug-resistance and an upregulation of IMP-1 (48).  Increased 
expression of IMP-1 was proposed to enhance expression of multi-drug-resistance factor 1 
(MDR1) by preventing MDR1 mRNA degradation via endonucleases, as had been previously 
observed for c-Myc (18).   Additionally, it was demonstrated that IMP-1 promotes the expression 
of various bona fide let-7 targets including KRAS, Lin-28B and c-Myc (22).   
It remains poorly understood how the transcription of IMP-1 is regulated and how it 
might be modulated by epigenetic mechanisms. In contrast, there is substantial evidence for a 
significant role of post-transcriptional mechanisms directing the control of IMP-1 expression.  
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The let-7-axis appears to emerge as a highly conserved regulatory mechanism that antagonizes 
the expression of IMP-1. This supports the view that IMP-1 enhances tumor cell aggressiveness, 
because the let- 7 family of microRNAs is considered to exhibit a tumor suppressive role in most 
malignancies (49). Nonetheless, substantial effort is required to enhance our understanding of 
how the expression of IGF2BPs is modulated by the interplay of transcriptional and post-
transcriptional networks.  This will provide essential insights into how IMP-1 function is 
controlled during development and becomes dysregulated in diseases, such as cancer. 
 
Importance of IMP-1 in Cancer 
 
Consistent with its role in tumor growth and progression, IMP-1 expression is up-regulated by c-
Myc (50) and β-catenin (19), and it  is a major regulatory target of let-7 microRNA (47).  
Reduced expression of let-7 microRNA is one of the most common regulatory alterations in 
cancer. Overexpression of IMP-1 results in enhanced cell proliferation (15,51,52), suppression of 
apoptosis (22) and resistance to taxanes and other anticancer drugs (48,53).  Expression of IMP-1 
is associated with a poor prognosis in ovarian, lung, and colon cancer (15,32,54,55) (Figure 1.4).   
IMP-1, through its capacity to bind to and stabilize mRNAs, either directly or indirectly 
increases expression and activity of key oncogenic proteins such as c-Myc, ERK, MDR1, and 
NF-B. We, and others, find that RNAi knockdown of IMP-1 in cell lines from several types of 
cancers reduces c-Myc levels, inhibits cell proliferation and triggers apoptosis (15,19,25).  IMP-1 
binds to MDR1 (multidrug resistance protein 1/P-glycoprotein) mRNA, stabilizing MDR1 
mRNA, leading to overexpression of MDR1 and resistance to anticancer drugs (18,48,53). 
MDR1 carries out ATP-dependent pumping of xenobiotics and anticancer drugs out of cells. 
Overexpression of MDR1 is a common mechanism of resistance to anticancer drugs.  RNAi 
knockdown of IMP-1, or expression of let-7 miRNA, reduces the level of IMP-1, destabilizes 
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and down-regulates MDR1 and increases sensitivity of cancer cells to killing by therapeutically 
relevant concentrations of taxol, vinblastine and other anticancer drugs (48,53).  IMP-1 binds to 
and stabilizes the mRNA encoding the ubiquitin ligase β-TRCP1 (20,51,56) leading to 
ubiquitylation and degradation of I-B, resulting in release and activation of NF-B (20,51,53).  
Elevated NF-B expression is common in cancer and tumor-promoting inflammation  is an 
“enabling characteristic” in cancer (57).  As summarized in Table 1.2, IMP-1/IGF2BP1/CRD-BP 
is expressed in diverse cancers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Kaplan Meier analysis of overall survival in patients with ovarian (A), lung (B) 
or colorectal cancer (C) that is IMP-1/CRD-BP positive or negative.  Adapted from Kobel 
M et al, Oncogene 2007; Dimitriadis E et al., International Journal of Cancer 2007; Kato T 
et al, Clinical Cancer Research 2007.   
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Table 1.2.  Expression of IMP-1 in human cancers 
Cancer Method Incidence References 
Breast RT-PCR 59% (69/118) (58) 
Ovarian IHC 69% (73/106) (15) 
Melanoma IHC 34% (13/38) (51) 
Non-small cell lung RT-PCR  27% (4/11) (25) 
Pancreatic Northern 33% (5/15) (59) 
Colorectal RT-PCR 81% (17/21) (60,61) 
Hodgkin lymphoma IHC 94% (101/108) (62) 
Adapted from Bell J., et al., Cell. Mol. Life Sci., 2013. 
 
Current Limitations 
One challenge in conducting studies on IMP-1 is the lack of specificity of currently available 
antibodies.  Although we have achieved significant paralogue specificity for IMP-1, which 
allows for a largely unbiased analysis of IMP-1 expression in most cancer-derived cells, we 
currently cannot exclude slight paralogue cross-reactivity of monoclonal antibodies for IMP-3 at 
high protein concentrations (Figure 1.5).  
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Figure 1.5. Specificity of IMP-1 and IMP-3 antibodies in detecting recombinant purified 
IGF2BPs.  Indicated amounts of purified, recombinant IMP-1, IMP-2, or IMP-3 were 
purified and blots were probed with either IMP-1(Cell Signaling Technology D33A2) or 
IMP-3 (Abcam:Ab124959) antibody.  There is no cross reactivity of the IMP-1 antibody 
and enhanced cross reactivity of the IMP-3 antibody with increasing amounts of protein 
loaded.  Western blot provided by Dr. Chengjian Mao. 
 
Despite this limitation, we have shown the specificity of our tools, by performing RNAi 
knockdown of IMP-1 and assessing the levels of IGF2BP paralogs both by Western blot and 
qRTPCR.  The similarity in paralogue kDa size and amino acid sequence similarity makes 
differentiation of paralogues difficult by Western blot, therefore confidence in antibodies and 
siRNAs is critical.  Additionally, because much of the IMP research is in the context of cancer 
using immunohistochemistry, it is essential to generate and use paralogue-specific antibodies in 
these experiments. 
 
Thesis Synopsis 
The work described herein primarily focuses on identification of novel small molecule inhibitors 
of IMP-1.  IMP-1 is an important, but untargeted protein in human cancer. Because the oncofetal 
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mRNA-binding protein IMP-1 regulates the levels of diverse proteins important in cancer (Fig. 
2), targeting this master regulator of oncogenic mRNA degradation with small molecules has 
great therapeutic potential (50,63). This approach combines the benefits of RNAi (degradation of 
target mRNAs) with improved biological stability and pharmacokinetics (63).  Most currently 
used chemotherapeutics are quite toxic in part because they kill both cancer cells and rapidly-
dividing non-malignant cells.  IMP-1 is expressed at high levels in fetal cells and cancer cells 
and is nearly absent in most adult cells (64). Therefore, targeting IMP-1 selectively targets 
cancer cells, and holds great therapeutic promise. 
 In Chapter 2, we describe development and optimization of an in vitro method, 
fluorescence anisotropy microplate assay (FAMA), for use in high throughput screening (HTS).  
In a pilot study, we screened 17,600 small molecules using FAMA as proof of principle that we 
could identify inhibitors of IMP-1 binding to c-Myc RNA using this method.  In Chapter 3, we 
expanded upon our initial findings that FAMA was robust and reproducible for HTS, and 
conducted a screen of approximately 150,000 small molecules and identified 2-{[(5-bromo-2-
thienyl)methylene]amino}benzamide (BTYNB) as our lead small molecule inhibitor.  Based on 
the exciting results presented in Chapter 3, we believe that we have identified the first small 
molecule inhibitor of IMP-1 that not only works in vitro, but inhibits cell proliferation and 
colony formation in IMP-1 positive cancer cells.  We have also shown that BTYNB treatment 
leads to decreased mRNA levels in a panel of IMP-1 targets.  This result highlights BTYNB’s 
use as both a potential therapeutic agent and as a molecular probe, enhancing our understanding 
of IMP-1’s function in cancer cells.  In addition to studying small molecule inhibitors of IMP-1, 
we were also interested in understanding whether or not there are novel molecular targets of 
IMP-1.  In Chapter 4, we describe identification of Protein Kinase C alpha (PKC) as a novel 
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molecular target of IMP-1.  In silico analysis of IMP-1 RNAi knockdown in HEK 293T cells 
using publically available arrays (65) revealed PKCα mRNA as a likely molecular target of IMP-
1.  Knockdown of IMP-1 in HEK 293T cells resulted in a decrease in PKCα protein, while 
overexpression of IMP-1 in the same cell line resulted in an increase in PKCα mRNA. Compared 
to PKCα mRNA levels in cells treated with non-coding control siRNA, RNAi knockdown of 
IMP-1 in IGROV-1 and SK-MEL2 cells led to a decrease in PKCα mRNA.  Similarly RNAi 
knockdown of IMP-1 lead to a decrease in PKCα protein levels in the same cell lines.  One 
potential mechanism by which IMP-1 might increase PKCα levels is by binding to the IMP-1 
binding sequence motif (UUUAY), which has previously been identified in Drosophila (66) and 
is found in the 3’-UTR of PKCα mRNA.  Previous work found that IMP-1 stabilization of MITF 
mRNA interferes with microRNA 340-mediated degradation and that these sites were juxtaposed 
in the 3’UTR of the MITF transcript (44).  Using miRWalk and other tools for predicting micro 
RNA (miR) sites in the mRNA 3’-UTR, miR-340 was the top miR for PKCα. This is consistent 
with the idea that PKCα mRNA is a molecular target for IMP-1.  This thesis closes with 
conclusions from my work and describes some future directions that may arise from this body of 
research. 
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CHAPTER 2 
 
High-Throughput Fluorescence Anisotropy Screen for Inhibitors of the Oncogenic mRNA-
binding Protein, IMP-1 
 
 
Notes and Acknowledgements: 
 This chapter is adapted from the following publication: Mahapatra L, Mao C, Andruska 
N, Zhang C, Shapiro DJ (2014) High-throughput fluorescence anisotropy screen for inhibitors of 
the oncogenic mRNA binding protein, IMP-1. J Biomol Screen. 19:427-436. The publication has 
been modified for this chapter and is reprinted with permission from the publisher. The original 
publication is available from http://jbx.sagepub.com/ and using DOI: 10.1177/ 
1087057113499633.   This work was supported by the National Institute of Cancer (NCI) 
Award: 1 R21 CA173527-01 and the University of Illinois College of Medicine Hazel Craig 
Research Fellowship.   
 
 
ABSTRACT 
 
Cancer cell proliferation is regulated by oncogenes, such as c-Myc. An alternative 
approach to directly targeting individual oncogenes is to target IMP-1, an oncofetal protein 
that binds to and stabilizes mRNAs, leading to elevated expression of c-Myc and other 
oncogenes. Expression of IMP-1 is tightly correlated with a poor prognosis and reduced 
survival in ovarian, lung and colon cancer. Small molecule inhibitors of IMP-1 have not 
been reported. We established a fluorescence anisotropy/polarization microplate assay 
(FAMA) for analyzing binding of IMP-1 to a fluorescein-labeled 93 nucleotide c-Myc 
mRNA target (flMyc).  This highly robust (Z’ factor = 0.60) FAMA-based high throughput 
assay was used to screen 17,600 small molecules and lead to the successful identification of 
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inhibitors of IMP-1 binding to c-Myc.  Our design strategically filters out toxic non-specific 
inhibitors using an early cell based assay in control cells lacking the target protein.  
Importantly, the first small molecule for IMP-1 identified by the in vitro high throughput 
screen selectively inhibited proliferation of IMP-1 positive cancer cells with very little or no 
effect on proliferation of IMP-1 negative cells.  
 
INTRODUCTION 
 
The oncofetal mRNA binding protein IMP-1/CRD-BP/IGF2BP1 is a multifunctional mRNA 
binding protein with important roles in mRNA degradation (1-3), translation (4), and localization 
(5).  Overexpression of IMP-1 results in enhanced cell proliferation (6),
 
suppression of apoptosis 
(7), and resistance to taxanes and other anticancer drugs (8, 9).
 
Kaplan-Meier plots show that 
expression of IMP-1 is tightly correlated with a poor prognosis in ovarian, colon and lung cancer 
(10-12).
 
Consistent with an important role in tumor growth and progression, IMP-1 expression is 
up-regulated by c-Myc (13)
 and β-catenin (14), and it is a major regulatory target of let-7 
microRNA (15).
  
IMP-1, through its capacity to bind to and stabilize mRNAs, increases 
expression and activity of key oncogenes including c-Myc, K-Ras and ERK.    
IMP-1 binds to a specific sequence that regulates the stability of c-Myc mRNA, 
stabilizing c-Myc mRNA, increasing levels of c-Myc mRNA and protein and increasing cell 
proliferation (12, 13).  RNAi knockdown of IMP-1 in cell lines from several types of cancers 
reduces c-Myc levels, inhibits cell proliferation and triggers apoptosis (12, 14).  Additionally, 
IMP-1 binds to MDR1 (multidrug resistance protein 1/P-glycoprotein) mRNA, stabilizing 
MDR1 mRNA, leading to overexpression of MDR1 and resistance to anticancer drugs (1, 8, 9). 
RNAi knockdown of IMP-1, or expression of let-7 miRNA, reduces the level of IMP-1, 
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destabilizes and down-regulates MDR1 and increases sensitivity of cancer cells to killing by 
therapeutically relevant concentrations of taxol, vinblastine and other anticancer drugs (8, 9).  
Despite its emerging role in both tumor cell proliferation and multidrug resistance, small 
molecule modulators of IMP-1 have not been reported. 
To develop a quantitative real-time assay for determining binding of IMP-1 to target 
RNAs, we designed a high throughput screening (HTS) and developed a fluorescence anisotropy 
microplate assay (FAMA).  Using this assay, 17,600 test compounds were evaluated for their 
ability to inhibit binding of IMP-1 to a 93 nucleotide fluorescein-labeled c-Myc mRNA binding 
site (flmyc) (16).  Because the 93 nucleotide c-Myc RNA binding site was too large to synthesize 
commercially, we developed simple methods for in vitro synthesis and fluorescein-labeling of 
the RNA. 
Assays based on fluorescence anisotropy/polarization have emerged as alternatives to 
electrophoretic mobility shift assays (EMSA) that can be difficult to adapt for high throughput. 
These assays are based on changes in fluorescence polarization/anisotropy, which occurs on 
binding of a protein to a labeled RNA.  When polarized light excites a fluorophore, such as the 
fluorescein-labeled c-Myc RNA (flmyc), the relatively small fl-RNA usually undergoes 
rotational diffusion more rapidly than the time required for light emission (Fig. 2.1). Therefore, 
the position of the fl-RNA at the time of light emission is largely randomized, resulting in 
depolarization of most of the emitted light.  In contrast, when a protein, such as IMP-1 binds to 
the fl-RNA, the larger size and volume of the protein–fl-RNA complex causes rotation to be 
slower, increasing the likelihood that the protein–fl-RNA complex will be in the same plane at 
the time of light emission as it was at the time of excitation. Therefore, the emitted light remains 
highly polarized (Fig. 2.1).  FAMA is ideal for HTS because it is a homogenous, rapid, and real-
 18 
 
time assay to assess binding in solution. Fluorescence polarization/anisotropy methods have 
recently been successfully utilized in HTS to identify small molecule inhibitors of biologically 
relevant RNA-protein interactions involved in diseases such as influenza and Rift Valley fever 
virus (17, 18). 
In this study, we carried out an unusual purification that selects for biological activity of 
purified IMP-1, developed the flMyc RNA probe, and performed a pilot screen of 17,600 small 
molecules from a compound library in the University of Illinois High Throughput Screening 
Center.  From the pilot screen, we identified 33 verified hits that inhibited binding of IMP-1 to 
flMyc and met fluorescence intensity cutoffs.  Since our primary screen was set up to identify 
inhibition of IMP-1 binding to flmyc, it did not exclude toxic compounds.  We first retested the 
hits for specificity by evaluating their ability to inhibit binding of the steroid hormone receptor, 
progesterone receptor (PR), to its fluorescein-labeled DNA binding site (fl-progesterone 
response element; fl-PRE). This specificity test was only moderately successful in filtering out 
compounds that subsequently proved toxic in IMP-1 negative cells.  Although previous pilot 
screens often used orthogonal validation assays such as EMSA and filter binding, these methods 
may not fully recapitulate the complex milieu of living cells. Therefore, we assessed how 
effectively and selectively the hits inhibited a key activity of IMP-1; stimulation of cell 
proliferation. To establish a cell-based assay to filter the hits, we used RNAi knockdown of IMP-
1 to confirm that IMP-1 expression was essential for proliferation of IMP-1 positive cells and 
that IMP-1 RNAi knockdown had no effect on proliferation of IMP-1 negative cells. The cell-
based assay identified a substantial number of hits as toxic in the IMP-1 negative cells. This 
indicates that an early assay in cells that lack the target protein functions as a rapid filter to 
eliminate small molecules exhibiting non-specific binding and toxicity. Based on our findings a 
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two-step screening strategy in which an initial biochemical screen using purified protein 
identifies hits that target the desired protein-RNA interaction, followed by a cell-based assay to 
filter out non-specific and toxic hits. This approach allowed us to identify a lead as the first 
selective small molecule inhibitor of IMP-1. 
 
MATERIALS AND METHODS     
Unless otherwise stated, average + SEM is reported for experiments where SEM equals  
σ/sqrt (n), where σ represents the population standard deviation and n is the sample size. 
 
Compound Libraries  
The pilot screen chemical library used part of a library of commercially available small 
molecules from the Chembridge Microformat Library that is maintained in the University of 
Illinois High Throughput Screening Center.  Compounds are stored at -20°C and arrayed in 384-
well plates at concentrations of 1 or 10 mM in DMSO.  
 
Protein Purification  
IMP-1 was purified as described by Nielsen et al. (19), with minor modifications, mostly 
suggested by Dr. J. Christiansen.  Untagged full-length IMP-1 in PET42a (Novagen) was 
expressed in a strain of BL21DE3pLysS expressing plasmid-encoded tRNAs for rare Arg, Ile 
and Leu codons (a generous gift of Dr. J. Christiansen). Following protein expression, cells were 
harvested, broken by sonication in 20 mM Tris–HCl, pH 7.8, 5 mM MgCl2, 100 mM KCl, 1 mM 
DTT and 1.4 μg/ml aprotinin, Triton X-100 was added to 0.4%, and cell debris was removed by 
centrifugation at 8,000 RPM at 4°C for 10 min. The supernatant was made up to 10% in 
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glycerol, and layered on a sucrose cushion consisting of 1.1 M sucrose, 20 mM Tris–HCl, pH 
7.8, 5 mM MgCl2, 100 mM KCl, 1 mM DTT and 0.1% Triton X-100 and centrifuged for 2 hours 
at 4°C at 40,000 RPM. The resulting pellet contains IMP-1 bound to polysomal mRNA. The 
pellets were washed in 20 mM Tris–HCl, pH 7.8, 5 mM MgCl2, 100 mM KCl, 1 mM DTT and 
0.1% Triton X-100.  IMP-1 was dissociated from polysomal mRNA by re-suspending the pellets 
in 20 mM Tris–HCl, pH 7.8, 5 mM MgCl2, 650 mM KCl, 1 mM DTT and 0.1% Triton X-100. 
The suspension was centrifuged for 1 hour at 4°C at 40,000 RPM. The supernatant was adjusted 
to 200 mM KCl and 10% glycerol before it was applied to a 2 mL Heparin–Sepharose column 
(Amersham Biosciences) equilibrated in 20 mM Tris–HCl, pH 7.8, 5 mM MgCl2, 200 mM KCl, 
1 mM DTT, 0.1% Triton X-100 and 10% glycerol. After washing with the equilibration buffer, 
the protein was eluted by the same buffer containing 350 mM KCl.  The indicated eluted 
fractions (E, elution) were resolved on a 10% SDS-PAGE gel and visualized by Coomasie blue 
staining.  Purified IMP-1 from fractions E7 and E8 was near homogenous and was used in our 
studies. 
Full-length FLAG-epitope tagged human PR-B (120 kDa) was purified from baculovirus-
infected insect cells produced at 5L BioReactor scale in a facility at the University of Colorado 
Health Sciences Center facility (20)  and was a generous gift of Prof. S. Nordeen.   
 
Synthesis of Fluorescein-labeled c-Myc RNA Probe 
The flMyc probe was produced essentially as we describe (87) with the minor modification of 
using the MEGAscript kit (Ambion) for in vitro transcription.  Standard palindromic cPRE/GRE 
(5’-f-CTAGATTACAGAACAATCTGTTCTTAC TCA-3’) were synthesized as previously 
described (21). Briefly, sense strand oligonucleotide was synthesized with fluorescein  (6-FAM) 
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at their 5′ ends using phosphoramidite chemistry and PolyPak™ II (Glen Research) purified by 
the Biotechnology Center (University of Illinois Urbana Champaign). Oligonucleotide 
concentrations were calculated from A260 and the labeled sense strands were annealed with 
equimolar amounts of unlabeled antisense strands. 
 
Fluorescence Anisotropy Assays   
The fluorescence anisotropy microplate assay (FAMA) buffer was modified from our earlier 
assay (16). Anisotropy change represents the difference between the anisotropy measured at each 
concentration of IMP-1 and the anisotropy value measured in the absence of IMP-1 (flmyc RNA 
alone). In competition experiments, unlabeled competitors were pre-mixed with the fluorescein-
labeled RNA probe before IMP-1 was added.  The anisotropy change for IMP-1 binding to 
flmyc-RNA with no competitor was set to 100%. Percent anisotropy change was calculated as 
follows: (anisotropy change (plus competitor)/ anisotropy change (no competitor))X100. 
FAMA for High Throughput Screening was performed in 384-well low volume, flat 
bottom microplates (Greiner Bio-One). The optimum IMP-1 protein (10 nM) and flmyc RNA (1 
nM) concentrations for the assay were chosen because they result in approximately 90% of 
maximal binding.  Assays contained 20 mM Tris-HCl, pH 8.0, 150 mM KCl, 1 mM EDTA, 1 
ng/l tRNA, 1 ng/l heparin, 0.4 U/l RNasin, and 500 ng/l RNase-free BSA.  A sequential 
protocol was used to assess changes in anisotropy, intrinsic fluorescence of test compounds, the 
compounds’ influence on the anisotropy signal of the probe alone, and the ability of compounds 
to inhibit binding of IMP-1 to flmyc.  First, plates were loaded with 10 l binding buffer 
containing fluorescein-labeled c-Myc RNA probe (2-fold in binding buffer) with a Matrix 
PlateMate Plus dispenser (Thermo Scientific) in every well.  Then 100 nL of each test compound 
 22 
 
from the 1 mM compound plates was transferred to each well of the test plates using the Matrix 
PlateMate Plus robotic pin transfer apparatus. Then fluorescence polarization/anisotropy (FP/FA) 
was determined using an Analyst HT Plate Reader (Molecular Devices).  FITC FP 480 
(excitation) and 535 (emission) filters were used.  Then, 10 l of binding buffer and IMP-1 
protein (final assay concentration 10 nM) was added to each well except control wells that 
contained received 10 l of binding buffer.  FP/FA for each well was measured after 15 minutes, 
when the assay had reached equilibrium as determined from kinetic studies of the ON and OFF 
rate of IMP-1 binding to flMyc.  Thus, in the final assay compounds were tested at 5 M for 
their ability to inhibit binding of 10 nM of IMP-1 to 1 nM flMyc RNA probe.  Columns 23 and 
24 on each plate contain DMSO and no test compounds and these wells served as screening 
controls.   
For follow-on tests for specificity, fluorescein-labeled progesterone response element 
(flPRE) was diluted to 1 nM in a binding buffer containing 15 mM Tris-HCl, pH 7.9, 100  mM 
KCl, 1 mM dithiothreitol (DTT), 5% glycerol, 0.05% Nonidet™ P-40 (NP-40), 100 ng poly 
dI:dC (non-specific competitor), and 250 ng/l BSA.  The protocol for assessing change in 
anisotropy was similar to the one described above for the IMP-1:flMyc experiments, except that 
compounds were tested at a final concentration of 10 M for their ability to inhibit binding of PR 
to the flPRE DNA probe.  The concentration of PR used in the follow-on assay, 35 nM, is not 
saturating and is highly responsive to inhibition. 
Data Analysis and Hit Scoring 
To determine the robustness of our screening assay, the Z’ factor for each plate was calculated as 
previously described (22).
   
A Z’ factor greater than 0.5 describes a robust assay suitable for high 
 23 
 
throughput screening (22).
 
The results from the pilot screen were further analyzed using a simple 
program we developed to evaluate and score different parameters and identify the most 
promising compounds from the HTS. Initially, compounds that altered the overall fluorescence 
intensity by >30% compared to control wells were considered as either enhancers or quenchers 
and were excluded from further analysis.  The remaining compounds were evaluated for percent 
inhibition which was calculated relative to the assay plate control wells, where % inhibition = (1-
((mAComp – mAMin)/( mAMax – mAMin))) X100, where the assay minimum (mAMin) is flMyc RNA 
alone and the assay maximum (mAMax) is flmyc with IMP-1 protein.  Although there is no 
universally accepted standard of what change in signal constitutes a “hit” suitable for further 
evaluation, some researchers consider that any small molecule that results in a change of more 
than three standard deviations from the mean is appropriate for further study. The average 
change in anisotropy for the compounds in the pilot HTS was 86.7 mA ± 6.7.  The S.D. is 7.7%, 
and 3× S.D. is ∼25%. We therefore carried out further analysis of small molecules that, when 
present at 5 μM, altered the average change in anisotropy for binding of IMP-1 to flMyc by at 
least 25%. Compounds that met fluorescence intensity criteria and the percent inhibition cutoff 
were considered to be primary hits and were cherry-picked for follow-on assays. 
 
Cell Culture and siRNA Transfection                                                                                                                                                           
IMP-1 positive IGROV-1 ovarian cancer cells and IMP-1 negative PC-3 prostate cancer cells 
were used in cell-based experiments.  IGROV-1 cells were maintained in phenol-red free RPMI 
1640 with 10% fetal bovine serum (FBS) and PC-3 cells were maintained in DMEM-F12 with 
10% FBS. Cells were grown in monolayer and were maintained at 37° C with 5% CO2.  IGROV-
1 and PC-3 cells were plated in 96-well plates at a density of 1,000 cells/well and transfected 
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with an IMP-1 siRNA SMARTpool (Dharmacon) or a non-coding control siRNA using 
Dharmafect 1 transfection reagent (Dharmacon) according to the suppliers protocol.  5 days after 
transfection cell viability was determined using CellTiter 96 Aqueous One Solution Reagent 
(Promega).  For both cell lines relative cell proliferation was calculated as previously described 
(23). 
 
Testing Hits for Inhibition of Cell Proliferation  
IGROV-1 and PC-3 cells were maintained and plated in 96-well plates as described above. Each 
cell line was plated in growth medium 24 hours before treatment. Treatment medium containing 
either 0.4% DMSO (vehicle) or inhibitor compounds at a final concentration of 20 M in 
DMSO. After 3 days, cell viability was determined using Promega CellTiter 96 Aqueous One 
Solution Reagent (MTS). For each compound percent inhibition of cell proliferation was 
calculated relative to assay plate DMSO controls, which were set to 0% inhibition.  Small 
molecules were considered potential leads if percent inhibition of proliferation of the IMP-1 
positive IGROV-1 cells was at least 3 fold higher than percent inhibition of the control IMP-1 
negative PC-3 cells.  
 
Western Blots  
Cells were trypsinized, resuspended in their respective culture media, and plated into 6-well 
plates at 300,000 cells/well.  Cells were harvested, washed in ice-cold phosphate-buffered saline 
(PBS), and whole-cell extracts were prepared in lysis buffer containing 1X 
radioimmunoprecipitation assay (RIPA) buffer (Millipore), 1 mM EGTA, 30 mM NaF, 2.5 mM 
sodium pyrophosphate, 1 mM sodium orthovanadate, 1mM β-glycerol phosphate, 1 mM 
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phenylmethyl-sulfonyl fluoride, and 1 tablet of protease inhibitor cocktail (Roche, Indianapolis, 
IN). Cells were collected, and debris was pelleted by centrifugation at 15,000 g for 10 minutes at 
4°C. The supernatants were collected and stored at −20°C. Then, 20 µg total protein was loaded 
onto 10% (v/v) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels, 
separated, and transferred to nitrocellulose (GE Healthcare). IMP-1 protein was detected using 
IMP-1 antibody (sc-21026, Santa Cruz, CA) and β-actin internal standard was detected using 
antibody A1978 (Sigma). 
 
RESULTS 
 
Validation of the High Throughput Screening Assay  
We developed the fluorescence anisotropy microplate assay (FAMA) for analyzing the 
interaction of DNA and RNA binding proteins with their recognition sequences (16, 21).  In 
demonstrating the utility of FAMA for analysis of RNA-protein interactions, we examined the 
ability of CRD-BP/IMP-1 expressed in E. coli and renatured from inclusion bodies to bind to a 
fluorescein-labeled c-Myc (flMyc) RNA binding site.  Binding was low-affinity with an apparent 
KD of several hundred nM (16). Christiansen, Nielsen and coworkers reported that epitope 
tagged IMP-1 binds poorly to RNAs (24) and developed an expression system for recombinant 
untagged IMP-1 using E. coli stably expressing several rare tRNAs and a purification protocol 
that selects for biologically active IMP-1(19).  We expressed and purified IMP-1 using an update 
of this expression-purification system (Fig.2. 2A) and obtained purified untagged IMP-1 that was 
>90% homogeneous by SDS polyacrylamide gel electrophoresis (Fig. 2.2B).  
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To identify small molecule inhibitors that target IMP-1, we used modified binding 
conditions and a far more active IMP-1 preparation to update and improve our earlier assay for 
IMP-1 binding to flMyc (16).
 
 Purified untagged recombinant IMP-1 exhibited saturable high-
affinity binding to the fluorescein-labeled 93 nucleotide (nt) c-Myc RNA site (starting at nt 
1705), which contains the IMP-1 binding site. Under these binding conditions, the apparent Kd 
(the protein concentration at which 50% of the probe was bound) for IMP-1 binding to the flMyc 
was ∼3 nM (Fig.2. 3A).  Based on the binding data, we selected 10 nM IMP-1 for screening. 10 
nM IMP-1 yields approximately 90% of maximum binding to flMyc, resulting in a large 
anisotropy change (ΔmA) and a robust assay, while remaining highly responsive to inhibition by 
small molecules. In this assay, small molecules inhibitors will reduce the anisotropy change seen 
on binding of IMP-1 to flMyc (Fig. 2.1).  
Binding of IMP-1 to the flMyc RNA is sequence and structure specific. Because IMP-1 
binds unstructured single-stranded RNA, we tested the possibility that IMP-1 primarily interacts 
with the charged phosphate backbone. With the identification of an important role for 
polyphosphate in blood clotting (25),
 
polyphosphate with a length similar to the flMyc RNA 
became available to us for testing. Even at 1,000 fold molar excess, polyphosphate does not 
compete for IMP-1 binding (Fig. 2.3B). Therefore, interaction with the charged phosphate 
backbone is not responsible for high-affinity binding of IMP-1 to RNAs.  Binding of IMP-1 to 
flMyc was specific, as tRNA, even at 1,000 fold molar excess, had minimal ability to compete 
for binding (Fig. 2.3B).  Addition of the unlabeled c-Myc RNA resulted in a concentration-
dependent reduction in binding.  A 2.5 fold molar excess of the unlabeled c-Myc RNA reduced 
binding of IMP-1 to flMyc by approximately 50% (Fig. 2.3B).  
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The performance of the optimized binding assay was evaluated for its stability.  Under 
our assay conditions, binding of IMP-1 to flMyc is highly stable at room temperature and 
insensitive to changes in DMSO concentration.  Using 10 nM IMP-1 and screening conditions, 
after 60 minutes at 25°C, activity was 97% of the initial activity (ΔmA at 60 min was 91.1±1.3 
vs. initial ΔmA of 94.1±0.3; Fig. 2.3C). DMSO at the concentration to be used in the screen, and 
at twice that concentration, had no effect on binding of IMP-1 to flMyc (Fig. 2.3D). Thus, our 
assay had the requisite qualities for evaluation in a medium-scale pilot screen. 
Pilot Screen for IMP-1 Inhibitors  
To validate the assay and to identify small molecules that inhibit binding of IMP-1 protein to 
flMyc RNA, we carried out a pilot screen using 17,600 compounds (Plates 1-50) from the 
Chembridge Microformat Library. The performance of the optimized binding assay for use in 
HTS was evaluated for robustness by calculating the Z’ factor for each of the 50 plates screened.  
The assay demonstrates robust performance with a mean Z’ factor of 0.60 ± 0.06 (average + 
S.D.) and a signal to noise (S/N) of 12.4 (Fig. 2.4A).  The average change in anisotropy for the 
compounds in the pilot screen was 86.7 mA ± 6.7 (average + S.D).  The statistical parameters of 
the pilot screen are summarized in Table 2. 1.   
For the primary screen, compounds exhibiting increases or decreases >30% in total 
fluorescence intensity compared to controls were considered as either enhancers or quenchers 
and were excluded from analysis. Similar cutoffs have been used on other FP/FA screens (26, 
27).
 
 For the remaining compounds, we chose a cutoff of at least 25% inhibition (which is ~3X 
S.D.) at a final compound concentration of 5 µM and identified 57 primary hits (hit rate 0.32%, 
57/17600).   Figure 2.4B is a scatterplot for the 17,600 compounds from the pilot screen.   
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To validate the 57 hits, we compared their ability to inhibit a control protein-nucleic acid 
interaction, binding of progesterone (PR), a steroid hormone receptor, to its DNA binding site, 
the fluorescein-labeled progesterone response element (flPRE) (Fig 2.5A) to their ability to 
inhibit IMP-1 binding to flMyc. Triplicate assays in small volume 384-well plates used the same 
method described for the primary screen. At 5 µM, 33 compounds inhibited binding of IMP-1 to 
flMyc by >25% (Fig 2.5B).   A substantial number of primary hits that did not pass the 
verification assay were close to the cutoff of 25% inhibition at 5 µM.  Our counter-screen for 
specificity used binding of PR to the flPRE in part because it exhibits a change in anisotropy 
whose magnitude is similar to that seen for the primary assay using IMP-1 and flMyc (Fig. 
2.5A).   Our aim was to quickly identify potential false positives that displayed high-affinity for 
non-specific nucleic acid sequence or binding proteins rather than for the IMP-1:cMyc 
interaction and to identify small molecules that display a high-affinity for DNA, such as 
ethidium bromide and other DNA intercalators.   To provide a stringent test for specificity, we 
evaluated the ability of the verified hits to inhibit binding of PR to the flPRE at 10 µM, twice the 
concentration used in the IMP-1 screen and verification assays.  As shown in Figure 2.5B, only 
3 of the 33 verified hits exhibited greater than 25% inhibition of PR:flPRE binding.  
 
Evaluating Hits for Inhibition of Cell Proliferation 
Elevated expression of IMP-1 in cancer cells is associated with increased cell proliferation, 
which likely stems from stabilizing c-Myc and other oncogene mRNAs.  Evaluating the ability 
of verified hits that inhibit binding of IMP-1 to c-Myc to also inhibit effects of IMP-1 on cell 
proliferation provides a critical test of their effect on a key cancer-related function of IMP-1.  To 
establish the cell proliferation assay, we carried out RNAi knockdown of IMP-1 in IMP-1 
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positive IGROV-1 ovarian cancer and in IMP-1 negative PC-3 prostate cancer cells (Fig. 2.6) in 
96-well plates using a control non-coding (NC) siRNA and IMP-1 siRNA.  After 5 days, MTS 
assays were performed and relative percent inhibition of cell proliferation was determined for 
each cell line (23).
 
 Compared to IGROV-1 cells transfected with the control siRNA, RNAi 
knockdown of IMP-1 caused an 80% decrease in IGROV-1 cell proliferation.  In contrast, 
compared to transfection with the control siRNA, transfection of the IMP-1 negative PC-3 cells 
with IMP-1 siRNA had no effect on cell proliferation (Fig. 2.6). 
We evaluated the effects of all the verified inhibitors from the in vitro pilot screen in cell 
proliferation assays in IMP-1 positive IGROV-1 cells and IMP-1 negative PC-3 cells. Our recent 
study identifying a small molecule inhibitor of androgen receptor confirms that PC-3 cells are a 
suitable toxicity control and are quite sensitive to small molecules exhibiting non-specific 
toxicity (28).
 
Data is shown for a lead inhibitor and for representatives of the other classes of 
small molecules (Fig. 2.7). The lead small molecule inhibits proliferation of IMP-1 positive 
IGROV-1 cells, with very little or no effect on IMP-1 negative PC-3 cells (Fig. 2.7).  Our lead 
small molecule inhibited binding of IMP-1 to flMyc (72+3.6% inhibition at 5 M) and does not 
inhibit binding of PR to the flPRE (-31 + 3.2% inhibition at 10 M).  Thus, the lead compound 
demonstrated efficacy and selectivity both in in vitro assays using purified proteins and in cell-
based assays. Additional evidence of the robust nature of our screen is shown by the fact that the 
lead inhibitor had a Z-score of -6.8 and was clearly differentiated from the other compounds on 
its HTS plate (Fig. 2.8).  
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DISCUSSION 
Expression of IMP-1 is implicated in several human cancers.  While Kaplan-Meier survival plots 
show a tight correlation between IMP-1 expression and survival (p <0.05 for ovarian, lung and 
colon cancer), IMP-1 is also strongly implicated in melanomas (6, 8, 29) and other cancers.  
IMP-1 is an oncofetal protein expressed in fetal cells and cancer cells and nearly absent in most 
somatic cells (30, 31).  Thus, IMP-1 is an excellent therapeutic target.  Although a high-affinity 
binding site for IMP-1 that is implicated in regulation of c-Myc mRNA degradation was 
identified a number of years ago, small molecule biomodulators to probe the actions of IMP-1 
and inhibit its activity in cancer cells have not been described. The substantial >90 nucleotide 
size of the high-affinity IMP-1 binding site in c-Myc mRNA, the lack of a clear consensus IMP-
1 RNA binding site (32,33), 
 
and wide variations in the affinity of observed IMP-1 preparations 
for RNA (1,16,19) all complicate development of a high throughput screen.  We show that 
purified IMP-1 binds with high-affinity and specificity to the c-Myc binding site.  Even at a 
1,000 fold molar excess, tRNA and polyphosphate had very little ability to compete with flMyc 
for IMP-1 binding (Fig. 2.3B). Thus, binding of IMP-1 to flMyc exhibited the requisite 
specificity for HTS.  
Our primary screen used an in vitro assay for inhibition of binding of purified IMP-1 to 
flMyc rather than an assay for inhibition of cell proliferation for several reasons.  In our hands, it 
is difficult to obtain the requisite reproducibility in cell-based assays for proliferation inhibitors 
in 384-well plates. More important, the in vitro assay using purified IMP-1 provides direct 
evidence that the primary hits actually inhibit the desired target—the IMP-1:flMyc interaction. 
Although recent studies show that IMP-1 stabilizes numerous mRNAs (32), we focused on 
identifying small molecule inhibitors of IMP-1 binding to c-Myc mRNA because the specific 
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sequence on c-Myc mRNA, the coding region determinant (starting at nt 1705),  is the best 
defined and most extensively studied IMP-1 binding site.  For other oncogene mRNAs stabilized 
by IMP-1, the IMP-1 binding sites are poorly defined (1, 3). We performed a pilot screen of 
17,600 small molecules and identified 30 compounds that showed selective inhibition of IMP-1 
binding to flMyc RNA and did not inhibit binding by the control DNA binding protein, PR to its 
DNA binding site, the PRE.  We further evaluated the candidate compounds in physiologically 
relevant assays that are important to IMP-1’s function by assessing cell proliferation in IMP-1 
positive and negative control cells.  By complementing in vitro assays to analyze specific 
inhibition of IMP-1:c-Myc binding with cell-based assays that evaluate an important biological 
endpoint in cancer cells, we identified a lead small molecule inhibitor of IMP-1.    
 Identifying inhibitors of RNA binding proteins is challenging (34, 35).
 
 Interestingly, we 
found that most of the compounds identified from our in vitro studies did not fail to work in 
intact cells; rather, they were toxic in a control cell line. This suggests that future high 
throughput screening campaigns to identify inhibitors of RNA-binding proteins may benefit from 
initial use of biochemical assays to identify specific inhibitors with early follow-on cell-based 
filtering assays to evaluate toxicity. This approach not only identifies specific inhibitors using in 
vitro binding, but characterizes a subset of those compounds exhibiting an important 
physiological function.  
This work represents a promising start towards identification of small molecule inhibitors 
of IMP-1 and describes a path for HTS to identify additional small molecule IMP-1 
biomodulators. The lead inhibitor we describe represents an important initial biomodulator for 
laboratory studies and further characterization; it is a candidate for structure-activity relationship 
studies and medicinal chemistry optimization to evaluate its ultimate therapeutic potential.  
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TABLES 
Table 2. 1.  Summary of Statistical Data from the Pilot Screen  
 
Number of compounds screened 17,600 
Total hits 57 
Overall hit rate (%) 0.30 
Percentage repeat 58 
Number of compounds repeated 33 
Mean Z’-factor 0.60 ± 0.06 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Schematic representation of Fluorescence Anisotropy Microplate Assay 
(FAMA) to evaluate binding of IMP-1 protein to flMyc RNA probe.  After excitation with 
polarized light, flMyc rotates rapidly and the emitted light is largely depolarized.  Binding 
of IMP-1 to the flMyc results in a much larger, less mobile complex.  Therefore, the emitted 
light is more highly polarized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Purification of IMP-1. (A) Scheme of the protein expression and purification 
method used. (B) Purification of IMP-1 by affinity chromatography in Heparin-Sepharose 
column. 
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Figure 2.3.  Specific, high affinity binding of IMP-1 to flmyc RNA.  (A) Dose response 
studies of binding of IMP-1 to flmyc. 1nM of flmyc probe and indicated concentration of 
IMP-1 were incubated.  Anisotropy change is the difference between flmyc + IMP-1 and 
flmyc alone. (B) Competition experiments to assess the specificity of IMP-1 binding to 
flmyc RNA. 10 nM IMP-1 protein was added to reactions containing 1 nM flmyc RNA, and 
the indicated molar excess of unlabeled specific c-Myc mRNA, or the non-specific 
competitors, tRNA, or polyphosphate. Anisotropy change minus competitor was set to 
100%.  (C) Stability of the IMP-1:flMyc complex at room temperature and at different 
DMSO concentrations. (D) Binding of IMP-1 to flmyc RNA is stable for 1 hour at room 
temperature. Measurements were made of the same wells over 120 minutes. DMSO at the 
concentration to be used in the screen (0.5%), and at twice that concentration (1%), had 
negligible effect on binding of IMP-1 to flMyc. The data in panels A-D represents the 
average ± SEM (n=4). 
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Figure 2.3 (continued) 
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Figure 2.4.  Assay validation and high throughput screening results. (A) Assessment of 
screen robustness for the 50 plates screened using the Z′ factor.  The dotted line 
demarcates a Z’ factor of 0.6, the average Z’ factor for the 50 plate pilot screen. (B) 
Scatterplot of 17,600 small molecules screened from 50 plates in pilot HTS. A percent 
inhibition >100% means the small molecule reduced the anisotropy to a level lower than 
was seen with flMyc alone. RFU (relative fluorescence unit) represents the sum of the 
fluorescence intensities in the parallel and perpendicular channel for a given compound 
and % inhibition= (1-(( mAComp – mAMin)/( mAMax – mAMin))) X100.  Data from HTS are 
single point assays.   
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Figure 2.5. Evaluation of hits for potency and specificity.  Hits from the primary screen 
were verified and evaluated for specificity in follow-on assays. (A)  Binding of purified PR-
b to flPRE DNA probe.  Increasing amounts of PR were incubated with 1 nM flPRE-DNA 
probe. Compounds were evaluated for specificity by testing compounds for inhibition of 
binding of PR to flPRE.  (B) Primary hits were tested at 5 M for the ability to inhibit 
binding of IMP-1 to flMyc RNA (black bars).  Specificity of the verified hits was evaluated 
by testing their ability to inhibit binding of PR to flPRE at 10 M (grey bars). Compounds 
that did not pass the verification assay were not assayed for inhibition of PR binding to 
flPRE and only data from all the verified hits is shown. Surprisingly, a substantial 
percentage of verified hits slightly increased binding of PR to the flPRE. The data in panel 
A and B represents the average ± SEM (n=4 (A); n=3 (B)). 
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Figure 2.6.  IMP-1 knockdown inhibits cell proliferation in IMP-1 positive cells. Top: 
Western blot of IMP-1 positive IGROV-1 ovarian cancer cells and IMP-1 negative PC-3 
prostate cancer cells.  For each cell line, cell number after transfection with the control 
non-coding siRNA was set to 100%. The data represents the average ± SEM (n=5).   
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Figure 2.7.  Scheme for categorizing representative compounds from the pilot screen.  
Compounds were categorized based on their properties in FAMA and cell proliferation 
studies.  Cell proliferation data for representative compounds in each category is presented 
below their structures and the Chembridge number is shown.  Compounds were assayed at 
20 M in IMP-1 positive IGROV-1 cells and in IMP-1 negative PC-3 cells.  The 4 categories 
(from left to right) are the lead IMP-1 inhibitor; a compound that passed the IMP-1 
inhibition and PR inhibition assays, but did not inhibit proliferation of either cell line; a 
compound that passed the IMP-1 and PR assays and exhibits non-specific toxicity because 
it inhibits proliferation of both the IGROV-1 cells and the IMP-1 negative PC-3 cells; and a 
compound that failed the specificity test because it inhibited PR binding to the PRE and 
also was toxic to the PC-3 cells. Set to 100% was cell proliferation for each cell line treated 
with DMSO vehicle. The data represents the average ± SEM (n=4). 
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Figure 2. 8. Scatter plot of Z-scores from the plate containing the lead inhibitor. The lead 
inhibitor identified from the screen, 6896009 (black dot circled in red) had a Z-score of  
-6.82 and was clearly differentiated from the other compounds on the plate.  
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CHAPTER 3 
A Small Molecule Inhibitor of the Oncogenic mRNA Binding Protein IMP-1/ 
IGF2BP1/CRD-BP Targets c-Myc mRNA and Inhibits Proliferation of Cancer Cells 
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ABSTRACT  
    Insulin-like growth factor 2 mRNA-binding protein 1 (IMP-1/IGF2BP-1/CRD-BP/ZBP1) 
binds to and stabilizes c-Myc and other mRNAs that are up-regulated in cancer. Although 
overexpression of IMP-1 is associated with a poor prognosis in most types of cancer, IMP-1 
remains untargeted and c-Myc has been difficult to target. Using a fluorescence anisotropy 
microplate assay (FAMA) high-throughput screen of ~150,000 small molecules, we 
identified BTYNB as a novel, small molecule that specifically inhibits IMP-1 binding to its 
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recognition sequence in c-Myc mRNA.  The potency of BTYNB in inhibiting binding of 
IMP-1 to c-Myc RNA in vitro correlated with its ability to specifically reduce the 
intracellular level of c-Myc mRNA. BTYNB destabilized c-Myc mRNA and strongly 
reduced the level of c-Myc protein. BTYNB also reduced the levels of other IMP-1 target 
mRNAs.   Consistent with BTYNB acting in cells through IMP-1, overexpression of IMP-1 
reverses BTYNB inhibition of cell proliferation and BTYNB has no effect on proliferation 
of IMP-1 negative cells. BTYNB was as effective as RNAi knock-down of IMP-1 in 
inhibiting proliferation of IMP-1 containing cancer cells. Notably, BTYNB completely 
blocked growth of IMP-1 containing melanoma and ovarian cancer cells in anchorage-
independent colony formation assays. BTYNB is the first small molecule that targets 
cancer-associated mRNAs by inhibiting binding of an mRNA stabilizing protein to its 
target mRNAs.  
 
INTRODUCTION  
Insulin-like growth factor II mRNA-binding protein 1 (IMP-1/IGF2BP1), also known as 
the c-Myc coding region determinant-binding protein (CRD-BP) and zipcode binding protein 1 
(ZBP1) binds to diverse cancer-associated mRNA targets.  IMP-1 binding to mRNAs increases 
their stability and can also influence translation and mRNA localization (11,14,26,66). IMP-1 
likely stabilizes target mRNAs by shielding them from degradation by endoribonucleases 
(14,18,39) and microRNAs (20).   
Several lines of evidence support the important role of IMP-1 in cancer.  IMP-1 binding 
stabilizes mRNAs that play critical roles in cell growth, proliferation, migration and 
inflammation (15,21,22,51). IMP-1 expression is up-regulated by c-Myc, -catenin and hypoxia 
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(19, 50, 52) and it is a major regulatory target of let-7 microRNA (47, 48). In cell culture, 
overexpression of IMP-1 results in enhanced cell proliferation (41, 51), suppression of apoptosis 
(22),  resistance to taxanes and other anticancer drugs (48, 53) and increased inflammation (20). 
Moreover, transgenic mice that overexpress IMP-1 develop mammary tumors and colorectal 
cancer (61, 67). IMP-1 is expressed in fetal cells, is expressed at extremely low (68) or 
undetectable levels in normal cells (69, 70) and is frequently re-expressed in cancer cells.  High 
levels of IMP-1 expression are associated with tumor recurrence and a poor prognosis in ovarian 
cancer, melanoma, breast (58), colon (22,  55,  60), lung (25,54), and other cancers (6). 
Although IMP-1 upregulates the expression of mRNAs important in cancer, including c-
Myc, CDC34, TRCP-1 and MDR1 (18, 19, 50), a conserved IMP-1 recognition sequence has 
not been identified. Instead of a classical long conserved binding sequence, IMP-1 exhibits high 
affinity binding to weakly conserved, extended, relatively unstructured G-poor regions 
containing short interaction motifs (12, 65, 71). Therefore, many IMP-1 target mRNAs are likely 
still unidentified (11, 38, 65).  The best-studied and most widely accepted IMP-1 target is the 
oncogene c-Myc.  IMP-1 binds to the coding region stability determinant in c-Myc mRNA, 
protecting c-Myc mRNA from endonucleolytic degradation (16, 18, 40).   In ovarian, lung, 
melanoma and other cells, RNAi knockdown of IMP-1 reduces c-Myc mRNA levels (13, 15, 43, 
48, 51, 52) and overexpression of IMP-1 increases c-Myc levels (22, 43, 48, 52).     
     Given its dramatically elevated expression in cancer cells and its role in diverse cancers, 
targeting IMP-1 with small molecule biomodulators is an attractive strategy for probing IMP-1 in 
cancer and ultimately for improving therapy (6).  Also, since c-Myc has proven difficult to target 
directly, reducing c-Myc levels by decreasing c-Myc mRNA stability by inhibiting the IMP-1—
c-Myc mRNA interaction represents a novel therapeutic strategy.  However, mRNA binding 
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proteins that play a role in cancer have proven challenging to target and small molecule 
biomodulators of IMP-1 and other cancer-related mRNA stabilizing proteins have not been 
reported. More broadly, despite their roles in diverse cell processes, with a few exceptions 
largely centered on proteins important in protein synthesis (72, 73), eukaryotic mRNA binding 
proteins have rarely been targeted with small molecule biomodulators.  
To identify small molecule biomodulators of IMP-1, we developed a high throughput 
fluorescence anisotropy/ polarization microplate assay (FAMA) (71). We screened ~150,000 
small molecules and here report a small molecule 2-{[(5-bromo-2-thienyl)methylene]amino} 
benzamide (BTYNB) that inhibits IMP-1 binding to a specific high affinity binding site in the 
coding region stability determinant of c-Myc mRNA.  We show that BTYNB, identified from an 
in vitro screen, functions in cells to reduce intracellular levels of c-Myc mRNA and protein, and 
also reduces levels of other IMP-1 target mRNAs.  Importantly, BTYNB inhibits cell 
proliferation and anchorage independent growth of IMP-1 positive cancer cells with no effect on 
IMP-1 negative cells, making it a candidate for further therapeutic evaluation. To our knowledge, 
BTYNB is the first small molecule inhibitor of a mammalian mRNA stabilizing protein.   
  
MATERIALS AND METHODS 
Proteins 
Human IMP-1 and FLAG-PR-B were expressed and purified as we described previously (71,74).   
Oligonucleotides 
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The flMyc probe was produced as previously described (71) and the palindromic cPRE/GRE (5’-
f-CTAGATTACAGAACAATCTGTTCTTACTCA-3’) was synthesized as previously described 
(75). 
Chemical Libraries 
The libraries screened were the ChemBridge Micro-Format
TM
 small molecule library obtained 
from ChemBridge
TM
 containing ∼150,000 small molecules, the Marvel library developed at the 
University of Illinois by K. Putt and Hergenrother (76)  containing ∼9,700 small molecules, and 
the NCI Diversity Set from NIH with ~1,990 small molecules. Columns 23 and 24 on each plate 
of the screening library contain DMSO and no test compounds and these wells served as 
screening controls.   
 
Plasmids 
Vectors for purifying IMP-1 and synthesizing c-Myc RNA probe have been previously described 
(71).  pET42a-IMP-1 codes for untagged full-length IMP-1, which was then expressed in a strain 
of BL21DE3pLysS expressing plasmid-encoded tRNAs for rare Arg, Ile and Leu codons (a 
generous gift of Dr. J. Christiansen).   pBS.cMyc contains the c-Myc mRNA coding region 
instability determinant (nucleotides 1705–1792) and this region was amplified using the 
following primers: 5′-CAGAGATGCATAATACGACTCACTATAGGGAGATGAATAA-
GCTGTAATATCAC-3′ (the T7 promoter sequence is underlined) and 5′-CCTAAAATTGAAT-
TGTTTACA-ATAG-3′.  pCMV-IMP-1 codes for full length human IMP-1 and pTZ18U is a 
carrier DNA used to normalize the total amount of DNA transiently transfected. 
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High Throughput Screening Using FAMA 
The fluorescence anisotropy microplate assay for analyzing binding of IMP-1 to the fluorescein-
labeled c-Myc RNA was performed as described (71). Assays were carried out at room 
temperature in black wall 384-well microplates (Greiner Bio-One, NC) using a sequential 
method with a final volume of 20 l containing 20 mM Tris-HCl, pH 8.0, 150 mM KCl, 1 mM 
EDTA, 1 ng/l tRNA, 1 ng/l heparin, 0.4 U/l RNasin, and 500 ng/l RNase-free BSA.  A 
sequential protocol was used to assess changes in anisotropy, intrinsic fluorescence of candidate 
compounds, the compounds’ influence on the anisotropy signal of the probe alone, and the 
ability of compounds to inhibit binding of IMP-1 to flMyc.   For high throughput screening, a 
master mix containing the flMyc probe was prepared at 4 °C. The master mix was divided into 
two parts. IMP-1 was added to one part to 10 nM in the final assays. First, using  a Matrix 
PlateMate Plus dispenser (Thermo Scientific, MA), plates were loaded with 10 l binding buffer 
containing fluorescein-labeled c-Myc RNA probe (2-fold in binding buffer) in every well.  Then 
100 nl of each test compound from the 1 mM compound plates was transferred to each well of 
the test plates using the Matrix PlateMate Plus robotic pin transfer apparatus. Then fluorescence 
polarization/ anisotropy (FP/FA) was determined using an Analyst HT Plate Reader (Molecular 
Devices, CA).  FITC FP 480 (excitation) and 535 (emission) filters were used.  Then, 10 l of 
binding buffer and IMP-1 protein (final assay concentration 10 nM) was added to each well 
except control wells that contained received 10 l of binding buffer.  FP/FA for each well was 
measured after 15 minutes, when the assay had reached equilibrium as determined from kinetic 
studies of the ON and OFF rate of IMP-1 binding to flMyc.  Thus, in the final assay, compounds 
were tested at 5 M for their ability to inhibit binding of 10 nM IMP-1 to 1 nM flMyc RNA 
probe. “Hits” from the primary screen were analyzed and scored as previously described (71). 
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Dose-response curves for selected compounds were carried out as described for the HTS 
screen except that each well contained the indicated concentration of test compound. To assess 
for compound specificity, PR assays were carried out in a buffer containing 15 mM Tris-HCl, pH 
7.9, 100  mM KCl, 1 mM dithiothreitol (DTT), 5% glycerol, 0.05% Nonidet™ P-40 (NP-40), 
100 ng poly dI:dC (non-specific competitor), and 250 ng/l BSA.  Fluorescein-labeled 
progesterone response element (flPRE) was diluted to a final concentration of 1 nM in this 
binding buffer. The concentration of PR chosen for use in the follow-on assay is not saturating 
and is highly responsive to inhibition. 
 
Cell Culture 
Unless otherwise indicated, cells were maintained at 37 °C in 5% CO2 in growth medium 
containing 1% penicillin and streptomycin and fetal bovine serum (FBS) (Atlanta Biological, 
Atlanta, GA).  IMP-1 positive IGROV-1, ES-2, SK-MEL2, and HEK 293T cells and IMP-1 
negative BG-1/MCF-7 and T47DKBLuc cells were used in cell-based experiments.  Cells were 
maintained in the following culture media.  IGROV-1, SK-MEL-2, and T47DKBLuc: RPMI-
1640, supplemented with 10% FBS; ES-2: McCoy’s 5A, supplemented with 10% FBS; BG-
1/MCF-7: MEM supplemented with 5% FBS; HEK 293T: DMEM-F12 supplemented with 10% 
FBS. 
 
MTS Cell Proliferation Assays 
Cells were harvested and plated in 96-well plates at a density of 1,000 cells/well.  The medium 
was replaced with treatment medium the following day, and plates were incubated at 37°C in 5% 
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CO2 for 3 days. 20 μl of CellTiter 96 Aqueous One Solution Reagent (Promega, WI) was added 
to each well and the cells were incubated at 37° C in 5% CO2 for 1 hour. A490 was then 
measured to assess cell viability. For each cell line, cell number was calculated from a standard 
curve of the number of cells plated versus A490 (77).  
RNAi Knockdown 
IGROV-1, ES-2, SK-MEL, BG-1, and T47DKBluc cells were plated in 96-well plates at a 
density of 1,000 cells/well and transfected with an IMP-1 siRNA SMARTpool (Dharmacon, CO) 
or a non-coding control (NC) siRNA using Dharmafect transfection reagent (Dharmacon, CO) or 
Lipofectamine 2000 (Invitrogen) according to the suppliers’ protocol.  5 days after transfection 
cell viability was determined using CellTiter 96 Aqueous One Solution Reagent (Promega, WI).  
For both cell lines relative cell proliferation was calculated as previously described (77). 
 
Transient Transfection 
HEK 293T cells were plated 1,000 cells/well in 96-well plates in 10% FBS and transfected the 
following day.  On the day of transfection, the medium was changed to Opti-MEM. DNA and 
Lipofectamine2000 (Invitrogen, CA) were diluted in Opti-MEM and incubated together for 20 
min before adding to the well. A total of 100 ng of DNA was transfected into cells in each well 
at a DNA:Lipofectamine2000 ratio of 1:3. 24 h after transfection, inhibitor to a final 
concentration of 10 µM or DMSO control were added to the cells and incubated for 48 h. Cells 
were lysed in 100 μl of passive lysis buffer (Promega, WI), and luciferase activity was 
determined using Dual-Luciferase Reporter Assay (Promega, WI).  
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 Soft Agar Colony Formation Assays 
 To assay anchorage-independent cell growth in soft agar, 1%, and 0.7% Select Agar (Invitrogen, 
CA) was prepared in water and warmed at 40°C before use. 1.5 ml of 0.5% bottom agar diluted 
in medium was added to each well of a 6-well cell culture plate and allowed to solidify at room 
temperature. Top agar was prepared by dilution in warm medium containing the various 
treatments.  SK-MEL2 cells were resuspended in 1.5 ml of 0.35% top agar at 10,000 cells/well 
and ES-2 cells were resuspended in 1.5 ml of 0.35% top agar at 8,000 cells/well.  For each cell 
line, cells were plated in 3 wells for each condition. The plates were kept at room temperature for 
30 min until the top agar solidified, then 0.5 ml of medium containing the respective treatments 
was added on top of the agar. Culture medium on top of the agar was changed every 3–4 days. 
Colonies were visible by 1 week and counted at day 21 using a dissecting microscope. 
Photographs of colonies were taken using a Zeiss AxioImager2 imaging system at 10× 
magnification. 
 
Western Blots 
SK-MEL2 cells were plated at 200,000 cells/well in 6-well plates in RPMI-1640 containing 10% 
FBS. Medium was replaced the next day with fresh medium containing the indicated treatments. 
Whole cell extracts were prepared after 72 hour treatment in 1× radioimmune precipitation assay 
(RIPA) buffer (Millipore, CA) containing protease inhibitor mixture (Roche Applied Science, 
IN). Extract (20 μg of protein/lane) was run on 10% SDS-PAGE gels and transferred to 
nitrocellulose membranes.  c-Myc antibody (Cell Signaling Technology, MA) was used at a 
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1:1000 dilution. The blot was stripped for 25 min and re-probed using a 1:10,000 dilution of β-
actin monoclonal antibody (Sigma, MO). 
 
Quantitative RT-PCR and mRNA Decay Analyses 
SK-MEL2 cells plated at 300,000 cells/well in 6-well plates in RPMI-1640 containing 10% FBS. 
Medium was replaced the next day with fresh medium containing the indicated treatments.  After 
72 hours, RNA was extracted, and mRNA levels were measured by quantitative RT-PCR as 
described (78,79). For stability experiments SK-MEL2 cells were treated with either DMSO or 
10 µM BTYNB for 24 hours and treated with 5 μM Actinomycin D (mRNA decay) and 
harvested at indicated time points.  36B4 mRNA level is used as the qRT-PCR internal standard. 
Primers used in qRT-PCR were: Myc forward primer (5’-CCGACGCGGGGACCCTATTC) and 
reverse primer (5’-AACGTTGAGGGGCATCGTCGC-3’); IMP-1 forward primer (5’- 
TGAACACCGAGAGTGAGACG-3’) and reverse primer (5’- CTCATCGGGGAT-
GTAGGAGA-3’); eEF2 forward primer (5’-GCACGTTCGACTCTTCACTG) and reverse 
primer (5’-CTGGAGATCTGCCTGAAGGA); CALM1 forward primer (5’-CTCGCTCCC-
TCTGCTCTTC) and reverse primer (5’-AGGGAGAAGGCTTCCTTGAA); Collagen 5ɑ 
forward primer (5’-GCTGTGAAGTTGCAGTAAACCTTGAGGG) and reverse primer (5’-
CATGGAAGAGATCTTGGGCT-CTCTCAA); βTRCP1 forward primer (5’ACCAACATGG-
GCACATAAACT) and reverse primer (5’-TGGCATCCAGGTATGACAGAAT); 36B4 forward 
primer (5′-GTGTTCGACAATGGCAGCAT) and reverse (5′-GACACCCTCCAGGAAGCGA). 
The fold change in expression of each gene was calculated using the ΔΔCt method with 36B4 as 
the internal control. 
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Statistical Analysis 
 Results are expressed as the mean ± S.E.M. of at least three independent experiments. Student's t 
test was used for comparison of the means between two groups. Significance was established 
when p < 0.05. The comparisons are described in the figure legends and are not shown in the 
body of the figures.  
 
RESULTS 
 
High Throughput Screen for Inhibitors of IMP-1 
To identify small molecules that inhibit binding of IMP-1 to its binding site in the coding region 
stability determinant of c-Myc mRNA, we developed a high throughput fluorescence anisotropy 
micro-plate assay (FAMA) (71). The assay is based on the increase in fluorescence 
anisotropy/polarization when IMP-1 binds flMyc RNA. The IMP-1-flMyc complex is larger than 
flMyc RNA. Compared to flMyc, the IMP-1-flMyc complex will exhibit slower rotation, 
increasing the chance that the IMP-1-flMyc complex will be in the same plane at emission as it 
was at excitation, resulting in an increase in fluorescence anisotropy. A small molecule that 
blocks IMP-1 binding to flMyc will reverse the IMP-1-mediated increase in fluorescence 
anisotropy/polarization.   
Screening was performed in vitro, using purified untagged IMP-1 and fluorescein-labeled 
c-Myc RNA in 384-well microplates. We screened small molecule libraries containing 
approximately 150,000 compounds and analyzed the results using screening software we 
developed and tested in a pilot study (71).  We identified 981 compounds that reduced anisotropy 
of the IMP-1-flMyc complex by >30%.   After rescreening and eliminating compounds that no 
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longer reduced the anisotropy change by >30%, displayed intrinsic fluorescence, or reduced the 
signal of the free flMyc probe, 300 structurally diverse compounds were selected for further 
testing.  Most of the small molecules excluded from further analysis either displayed intrinsic 
fluorescence, or reduced the signal by a little over 30% in the initial assay and slightly less than 
30% on retesting. The robust nature of our screen is shown by the fact that the lead inhibitor had 
a Z- score of –10.2. 
 Validated hits were evaluated using FAMA for specificity and potency in dose response 
studies.  Compounds that inhibited binding of IMP-1 to flMyc, with no effect in a control 
binding assay were further evaluated in cell-based assays for inhibition of cell proliferation, a 
critical readout for IMP-1 activity.  Compounds that inhibited proliferation of IMP-1 positive 
cells with no effect on IMP-1 negative cells were considered leads for further evaluation.  Figure 
3.1 summarizes the sequence of assays used to identify the lead inhibitor of IMP-1 action.  
 
BTYNB is a Structure-specific Small Molecule Inhibitor of IMP-1 Binding to c-Myc RNA 
 From the high throughput screen and initial follow-on studies we identified the lead small 
molecule 2-{[(5-bromo-2-thienyl)methylene]amino}benzamide (BTYNB) (Fig. 3.2A). We 
evaluated the potency, efficacy and selectivity of BTYNB in dose-response studies. BTYNB 
inhibited binding of IMP-1 to flMyc (504.7% inhibition at 5 M) and had negligible effects on 
binding of PR to flPRE at all concentrations tested, including 50 M (Fig. 3.2B).  A close 
structural relative of BTYNB, Compound 5226752, which shares 90% 3D similarity with 
BTYNB (Fig. 3.2A), had no effect on binding of IMP-1 to flMyc, or of PR to flPRE (Fig. 3.2C). 
To further probe the relationship between chemical structure and activity, we carried out a 
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limited study of structure activity relationships (SAR) and performed dose-response studies on 7 
additional structural relatives of BTYNB. Only one of the 7 compounds (Compound 531848) 
inhibited binding of IMP-1 to flMyc (Fig. 3.3) and its potency was poor (Fig. 3.3F). Thus, 
BTYNB is a structure selective inhibitor of binding of IMP-1 to flMyc.  
 
BTYNB Reduces the Level of IMP-1 Protein 
 Although in vitro assays, such as FAMA have the advantage of being homogenous and 
reproducible and are ideal for producing quantitative information on macromolecular 
interactions, FAMA does not fully recapitulate the complex environment of living cells. To test 
the effect of IMP-1 in intact cells, we initially used Western blot analysis to assess the IMP-1 
status of 31 cell lines from diverse tissues. Consistent with most data from tumor 
immunohistochemistry and microarrays, which support a role for IMP-1 in nearly all types of 
cancer except prostate cancer and estrogen receptor  (ER) positive breast cancer, IMP-1 was 
widely distributed but was nearly undetectable in prostate cancer cell lines and in ER positive 
breast cancer cell lines.  
To evaluate the effect of IMP-1 in cell lines from tumors that have proven difficult to 
target therapeutically and contain diverse levels of IMP-1, we selected IGROV-1 ovarian cancer 
cells, and SK-MEL2 melanoma cells as containing high and low levels of IMP-1, respectively 
and BG-1 and T47DKBluc breast cancer cells as IMP-1 negative cells containing undetectable 
levels of IMP-1 (Fig. 3.4). 
In vitro assays, such as FAMA cannot assess potential effects of small molecules on 
intracellular levels of their targets. To test whether BTYNB influences intracellular levels of 
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IMP-1, we evaluated the effect of increasing concentrations of BTYNB on levels of IMP-1 
protein in IGROV-1 and SK-MEL2 cells. BTYNB treatment resulted in a dose-dependent 
decline in IMP-1 levels in IGROV-1 (Fig. 3.5A) and SK-MEL2 cells (Fig. 3.5B). IMP-1 levels 
were clearly reduced at 10 M BTYNB, a concentration that inhibited binding of IMP-1 to 
flMyc by ~80% (Fig. 3.2B).   
 
BTYNB Reduces the Levels of Cancer-related IMP-1 mRNA Targets 
 Knockdown of IMP-1/IGF2BP1/CRD-BP reduces levels of IMP-1 protein and this is thought to 
destabilize IMP-1 target mRNAs, reducing levels of cancer-related mRNAs important in cell 
proliferation, migration, cancer enabling inflammation and metabolic regulation (6). In contrast 
to c-Myc, for which a well-characterized IMP-1 binding site has been identified (16, 24, 41, 80), 
specific interactions regions remain unknown for most cancer-related IMP-1 targets. Moreover, 
IMP-1 binding sites display limited sequence conservation. It was therefore unclear whether 
IMP-1 would display broad ability to influence levels of IMP-1 target mRNAs or would be 
restricted to effectiveness on c-Myc mRNA. We tested the effect of BTYNB on levels of several 
IMP-1 mRNA targets. These mRNAs were chosen because IMP-1 depletion was shown to 
reduce their levels and because they promote a diverse range of oncogenic activities. Target 
mRNAs implicated in tumor cell proliferation (CDC34, CALM1 [calmodulin]), migration 
(CDC34, Col5A [Collagen V,α1]), and tumor enabling inflammation (TRCP1) were tested (19-
22, 65). IGROV-1 and SK-MEL2 cells were maintained in 10 M BTYNB for 3 days and levels 
of CDC34, CALM1, TRCP1 and Col5A mRNAs were quantitated by qRT-PCR. Although the 
IGROV-1 cells contain several fold higher levels of IMP-1 than the SK-MEL2 cells (Fig. 3.4), 
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and might therefore be less effective in inhibiting binding of IMP-1 to its mRNA targets, 
BTYNB had similar effects on levels of CDC34, CALM1 and Col5A  mRNAs in the two cell 
lines. There was a statistically significant reduction in the level of CDC34, CALM1 and Col5A 
mRNA to approximately 30-70% of the levels in vehicle-treated controls (Fig. 3.6). In contrast, 
the level of TRCP1 mRNA declined dramatically in SK-MEL2 cells, but was only reduced 
modestly in the IGROV-1 cells (Fig. 3.6). These data demonstrate that BTYNB reduces the 
levels of a diverse set of cancer-related IMP-1 mRNA targets.  
 
BTYNB Reduces Levels of Eukaryotic Elongation Factor 2a and Inhibits Global Protein 
Synthesis  
Recent PAR-CLIP and RIP studies suggest more than 1,000 mRNAs as potential candidates for 
IMP-1 binding, with eukaryotic elongation factor 2 (eEF2) as a top predicted target (65). eEF2 is 
a gene that plays an essential role in protein synthesis. The ability of cancer cells to rapidly 
proliferate is dependent on basal translation rates and thus on eEF2 (81).  Furthermore, eEF2 is 
an important link between metabolic regulation in cancer and protein synthesis (82).  eEF2 is 
overexpressed in many cancers, including lung, colorectal, pancreatic, and breast and is an 
important molecular target in these cancers (83,84). Therefore, we examined the effect of 
BTYNB on eEF2 mRNA and protein in more detail. We compared the effect of BTYNB with 
siRNA knockdown of IMP-1.  
We treated IGROV-1 and SK-MEL2 cells with 10 M BTYNB for 72 hours and 
observed a ~2.5-fold decrease in eEF2 mRNA (Fig. 3.7A, 3.7B) and observed a decrease in 
eEF2 protein (Fig. 3.7C). To test whether the decline in eEF2 mRNA and protein reduced 
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protein synthesis, we measured the effect of BTYNB on incorporation of 
35
S methionine into 
protein. Consistent with its ability to reduce the level of eEF2, a rate-limiting protein in protein 
synthesis, BTYNB treatment elicited a significant decrease in protein synthesis (Fig. 3.7D).  
Consistent with earlier work suggesting eEF2 is a likely IMP-1 target, RNAi knockdown of 
IMP-1 in IMP-1 positive IGROV-1 ovarian cancer cells (Fig. 3.7E) resulted in a ~7-fold 
decrease in eEF2 mRNA levels (Fig. 3.7F) and a smaller, but clearly detectable, decrease in 
eEF2 protein (Fig. 3.7G).    
 
BTYNB Increases Degradation of c-Myc mRNA, Decreasing Expression of c-Myc mRNA and 
Protein 
Given that c-Myc is the best established and most extensively studied target of IMP-1, we 
tested whether BTYNB inhibits a known activity of IMP-1, the ability to regulate c-Myc mRNA 
stability (13,16,24). Binding of IMP-1 to the c-Myc coding region stability determinant protects 
c-Myc RNA against degradation, stabilizing c-Myc RNA, increasing the levels of c-Myc RNA, 
protein and enhancing cell proliferation (14,15,50).  In order to address the mechanism of action 
of BTYNB, we evaluated whether treatment with BTYNB increases c-Myc mRNA degradation, 
leading to a decrease in c-Myc mRNA and protein.  To investigate the effect of BTYNB on the 
degradation of c-Myc mRNA, we employed the widely used technique of blocking new mRNA 
synthesis using Actinomycin D and following the decay of c-Myc mRNA. SK-MEL2 melanoma 
cells were pre-treated with DMSO vehicle, or with 10 M BTYNB, mRNA synthesis was 
inhibited by addition of Actinomycin D and total RNA was isolated at the indicated times. The 
relative level of c-Myc mRNA at each time point was determined in three independent 
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experiments by normalizing to an internal control and setting the input amount of c-Myc mRNA 
to 100%.  Consistent with the data showing BTYNB-mediated increased degradation of c-Myc 
mRNA (Fig. 3.8A), BTYNB treatment reduced the level of c-Myc mRNA by ~3 fold (Fig. 
3.8B). BTYNB was as effective as RNAi knockdown in reducing the level of c-Myc mRNA 
(Fig. 3.8C). Likely because c-Myc protein is rapidly degraded and the level of c-Myc protein 
rapidly reflects the level of c-Myc mRNA, BTYNB elicited a robust decline in the level of c-
Myc protein (Fig. 3.8D).  
 
BTYNB Inhibits Proliferation of IMP-1 Positive Cancer Cells with no Effect in IMP-1 
Negative Cells 
Since overexpression of IMP-1 is associated with more aggressive tumors and a poor outcome in 
diverse cancers (15,54,55), and IMP-1 knockdown inhibits cell proliferation (15,48,51,52), and 
BTYNB influences levels of several oncogenes important in tumor cell proliferation, including 
c-Myc, CDC34 and eEF2, we evaluated the ability of BTYNB to inhibit proliferation of IMP-1 
positive cancer cells. Because of their stem-like character and very high level of IMP-1 (Fig. 
3.4), we included ES-2 ovarian cancer cells in the proliferation studies. Initially we assessed the 
effect of RNAi knockdown of IMP-1 on proliferation of IMP-1 positive and IMP-1 negative 
cells. Compared to a noncoding control (NC) siRNA, RNAi knockdown of IMP-1 reduced 
proliferation of IGROV-1, ES-2 and SK-MEL2 cells by ~7, 6 and 4 fold, respectively (Fig. 
3.9A-C). In contrast, RNAi knockdown of IMP-1 did not inhibit proliferation of the IMP-1 
negative BG-1 and T47DKBluc cells (Fig. 3.9D-E). Since IMP-1 knockdown did not inhibit cell 
proliferation and full-length IMP-1 was undetectable in these cells, (Fig. 4), we used BG-1 and 
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T47DKBluc cells as control IMP-1 negative cell lines. We hypothesized that if BTYNB was 
disrupting IMP-1 activity in the cells, treatment of the IMP-1 containing cells with BTYNB 
should result in a decrease in cell proliferation that was similar to what we observe with RNAi 
knockdown of IMP-1. In dose response studies, BTYNB elicited a robust dose-dependent 
inhibition of cell proliferation in IMP-1 positive cells (Fig. 3.10A-C), with IC50s of 2.3 M, 3.6 
M, and 4.5 M in ES-2, IGROV-1, and SK-MEL2 cells, respectively. Consistent with BTYNB 
acting by inhibiting binding of IMP-1 to target mRNAs, the dose-response curve for inhibition of 
cell proliferation (Fig. 3.10A-C) is similar to the dose-response curve for in vitro inhibition of 
binding of IMP-1 to flMyc (Fig.3.2B).  At 10 M BTYNB, compared to the vehicle-treated 
controls, proliferation of IGROV-1, ES-2 and SK-MEL2 cells was reduced by 8.4, 4.8 and 9.6 
fold, respectively. These data show that, at the reasonable dose of 10 M, BTYNB is as effective 
as RNAi knockdown in inhibiting proliferation of IMP-1 containing cancer cells.  
To test BTYNB for general cell toxicity, IMP-1 negative cells were tested in dose 
response studies and there was no dose-dependent effect on cell proliferation at all 
concentrations tested, including 50 M (Fig. 3.10D-E).   
 
BTYNB is a Structure-specific Inhibitor of IMP-1 Positive Cancer Cell Proliferation 
Having established that BTYNB only works in IMP-1 positive cells, we next tested whether the 
structure specificity seen in the in vitro binding assay using purified IMP-1 and flMyc (Fig. 3.2) 
was also observed in intact cells. We therefore evaluated the effect of the close structural relative 
of BTYNB, Compound 5226752, (structures in Fig. 3.2) on proliferation of the same 5 lines of 
IMP-1 positive and IMP-1 negative cells tested in Fig. 10 with BTYNB. Consistent with our in 
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vitro finding that Compound 5226752 did not inhibit binding of IMP-1 to flMyc (Fig. 3. 2B), at 
all concentrations tested, Compound 5226752 did not inhibit proliferation of IMP-1 positive and 
IMP-1 negative cells (Fig. 3.11).   
As a further test for off-target effects of BTYNB, we assessed whether BTYNB could 
inhibit estrogen mediated gene expression. We used IMP-1 negative T47DKBluc cells. 
T47DKBLuc cells contain estrogen receptor  (ER) and respond to addition of the estrogen, 
17-estradiol (E2) by activating expression of a stably transfected estrogen response element 
(ERE) luciferase reporter gene (78). Consistent with the absence of its IMP-1 target, BTYNB 
had no effect on expression of the ERE-luciferase gene (Fig. 3.11). Compound 522672 does not 
inhibit cell proliferation and BTYNB has no effect on cell proliferation or gene expression in 
IMP-1 negative cells (Fig. 3.10D-F, Fig. 3.11). Taken together these data indicate that BTYNB 
is a structure selective small molecule biomodulator with strong selectivity for IMP-1.   
 
Overexpression of IMP-1 in HEK 293T Cells Reverses BTYNB Inhibition of Cell Proliferation 
 The lack of effect of IMP-1 knockdown or BTYNB in IMP-1 negative cells and the similar 
dose-response curves for BTYNB inhibition of IMP-1 binding to flMyc and for inhibition of cell 
proliferation support BTYNB action through IMP-1. We postulated that if BTYNB inhibits cell 
proliferation by reducing binding of IMP-1 to pro-proliferation mRNA targets, then 
overexpression of IMP-1 might reverse the effect of BTYNB on cell proliferation. We used HEK 
293T cells because transfection of HEK 293T cells is unusually efficient, allowing assays of the 
effect of transient transfection on the entire cell population.  As shown in Figure 3.12A, 
compared to control 293T cells, IMP-1 levels increased in 293T cells transfected with 100 ng of 
 61 
 
CMV-IMP-1.  Consistent with its effect in other IMP-1 positive cell lines, when HEK 293T cells 
were treated with 10 µM BTYNB alone, or treated with BTYNB and transfected with a control 
plasmid, there was a significant decrease in cell proliferation compared to the cells treated with 
the vehicle control (Fig. 3.12B, C). Transfection with an IMP-1 expression plasmid abolished 
BTYNB inhibition of cell proliferation (Fig. 3.12D).  These results support the view that 
BTYNB acts through IMP-1.  
 
BTYNB Blocks Anchorage-independent Growth of IMP-1 Positive Cancer Cells 
Anchorage-independent growth is a hallmark of cancer cells. Growth in soft agar is often used to 
evaluate anchorage independence of human ovarian and melanoma cancer cells. Because 
IGROV-1 cell did not form colonies efficiently under our conditions, we tested the ability of 
BTYNB to inhibit colony formation of SK-MEL2 and ES-2 cells grown in soft agar. As shown 
in Figure 3.13, SK-MEL2 and ES-2 cells supplemented with medium containing DMSO vehicle 
formed large colonies (>0.5 mm) after 21 or 14 days, respectively (Fig 3.13A, 3.13C). The 
growth of these cells into colonies was completely inhibited by 10 μM BTYNB (Fig 3.13B, 
3.13D).  When colonies from all the wells of each treatment condition were counted, the DMSO-
treated control SK-MEL2 and ES-2 wells contained 83 and 102 colonies/well >0.5 mm in 
diameter, respectively (Fig. 3.13E, 3.13F). Notably, there were no colonies >0.5 mm in diameter 
in the BTYNB-treated wells (Fig 3.13 E, 3.13 F) and on average 8 and 13 small colonies/well 
less than 0.5 mm in diameter for SK-MEL2 and ES-2 cells, respectively. Thus, BTYNB potently 
inhibits anchorage-independent growth of ovarian and melanoma cancer cells. 
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DISCUSSION 
 
Our development of the first selective small molecule IMP-1 biomodulator is significant 
on several levels. Despite their ubiquitous roles in diverse cell processes, small molecule 
biomodulators of mammalian mRNA binding proteins have rarely been described. Thus, 
BTYNB serves as a prototype for this class of molecule. IMP-1’s role in cancer, and the cancer 
related proteins and microRNAs (miRNAs) that control IMP-1 expression, make targeting IMP-1 
especially attractive. IMP-1 is induced by the oncogene c-Myc and IMP-1 increases the level of 
c-Myc mRNA and protein by stabilizing c-Myc mRNA (16, 39, 80). This sets up a tumor 
promoting feed forward regulatory loop in which c-Myc induces IMP-1 and IMP-1 increases c-
Myc protein levels, enabling c-Myc to further induce IMP-1. Breaking this oncogenic feed-
forward regulatory loop (c-MycIMP-1c-Myc) using c-Myc inhibitors is challenging. 
Despite considerable effort, its important role in mediating cell proliferation in both normal and 
cancerous cells (85, 86), has made c-Myc difficult to target. Targeting IMP-1 with small 
molecule inhibitors presents an alternative method for targeting c-Myc and breaking the c-
MycIMP-1c-Myc feed forward regulatory loop.  
Reduced expression of let-7 family miRNAs is one of the most common regulatory 
alterations in human cancer (49).  IMP-1 is a major regulatory target of let-7 miRNA and 
disruption of let-7 increases IMP-1 levels (47, 48).  Since let-7 miRNAs are suppressors, 
targeting downregulation of let-7 miRNAs in human cancer is challenging. Small molecule 
inhibitors that target IMP-1 are an attractive alternative because IMP-1 is strongly upregulated 
by loss of let-7 miRNAs and transmits and expands the loss of let-7 signal by binding to and 
stabilizing mRNAs encoding c-Myc and other cancer-related mRNAs.  
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 The potential of BTYNB as a molecular probe for investigation of complex regulatory 
interactions is illustrated by the interplay between c-Myc, IMP-1 and let-7 miRNAs. Let-7 can 
reduce c-Myc mRNA levels by directly binding to the c-Myc mRNA 3’-UTR, or indirectly by 
reducing the level of IMP-1 leading to destabilization of c-Myc mRNA. BTYNB, by targeting 
part of this regulatory network by destabilizing c-Myc mRNA through inhibition of IMP-1, is an 
important new tool for investigation of this and other regulatory networks in cancer. 
When we initiated our efforts to identify a small molecule inhibitor of IMP-1, we 
envisioned targeting cancer through a synthetic lethality screen. IMP-1/IGF2BP1/ CRD-BP was 
thought to be an oncofetal protein, expressed in embryonic cells, nearly absent in adult cells and 
re-expressed in many cancers. In an important very recent report, an N-terminal deletion of 
CRD-BP/IGF2B1/IMP-1 was identified in adult tissues (68). Although the protein is missing 2 
RNA binding domains, it appears to be functional (68). While the significance of the variant 
form of IMP-1/IGF2BP1/ CRD-BP and its relation to the full-length form remain to be 
elucidated in detail, these data indicate that extremely low levels of IMP-1 are present in normal 
cells. The variant protein is present at extremely low levels in normal cells and there is a 100-
1,000 fold increase in IMP-1 levels in cancer cells relative to most normal adult cells. 
Development of BTYNB remains a successful application of a synthetic lethality screen to 
cancer cells. 
RNAi knockdown of IMP-1 showed that IMP-1 plays an important role in cell 
proliferation and that loss of IMP-1 reduces levels of c-Myc mRNA (15, 19, 21). Moreover, the 
proliferation phenotype of cancer cells in which IMP-1 or c-Myc have been knocked down is 
similar, suggesting that c-Myc is an important IMP-1 target (50).   Based in part on data from an 
endonuclease protection assay, a high affinity binding site for recombinant IMP-1 was identified 
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in the coding region instability determinant of c-Myc RNA (16). For our high throughput screen 
we used recombinant DNA technology and enzymatic coupling to synthesize a 93 nucleotide 
fluorescein-labeled RNA probe containing the c-Myc mRNA coding region instability 
determinant that binds IMP-1 and purified untagged IMP-1 (71, 87).  BTYNB was clearly the 
most potent and selective compound to emerge from our screen of ~150,000 compounds.  
mRNAs that interact with IMP-1 lack a strong conserved IMP-1 binding site. It was 
therefore unclear whether a small molecule identified as an inhibitor of binding of IMP-1 to its c-
Myc mRNA binding site would only reduce the level of intracellular c-Myc mRNA, or would be 
active on a wide range of IMP-1 targets. Because the sites at which IMP-1 binds to most of its 
known mRNA targets have not been characterized in detail, we could not evaluate BTYNB 
specificity using in vitro assays and small mRNA fragments from known IMP-1 targets. We 
therefore investigated the ability of BTYNB to down-regulate diverse mRNA targets in cancer 
cells. BTYNB was effective against a range of mRNA targets. Interestingly, despite the presence 
of a several fold higher level of IMP-1 in the IGROV-1 cells compared to the SK-MEL2 cells, 
BTYNB elicited a similar reduction in the levels of CDC34, CALM1 and Col5A mRNAs in the 
two cell lines (Fig. 6). However, TRCP1 mRNA levels were reduced much more dramatically 
in the SK-MEL2 cells than in the IGROV-1 cells. IMP-1 appears to stabilize target mRNAs 
largely by steric hindrance and interference with binding of nucleases and miRNAs (18, 20). 
Although the precise mechanism by which CDC34, CALM1, Col5A and eEF2 mRNAs are 
stabilized by IMP-1 is unknown, Spiegelman and coworkers have convincingly shown that IMP-
1 stabilizes TRCP1 mRNA by interfering with binding of miR-183 to sites in the 3’-UTR. 
Whether the increased effectiveness of BTYNB in downregulating TRCP1 in SK-MEL2 cells 
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reflects the lower level of IMP-1 in these cells, or is related to the miR-183 degradation system is 
unclear. 
The effectiveness of BTYNB in diverse IMP-1 positive cancer cell lines is likely related 
to its ability to down-regulate a broad range of cancer-related IMP-1 targets including, c-Myc, 
CDC34, TRCP1, CALM1, Col5A and eEF2 mRNAs. This enables BTYNB to inhibit 
anchorage dependent and anchorage independent cancer cell proliferation and global protein 
synthesis. Whether the ability of BTYNB to inhibit total protein synthesis is exclusively related 
to down-regulation of the rate limiting elongation factor, eEF2, or is due to some combination of 
BTYNB inhibition of cell proliferation resulting in a reduced requirement for new protein 
synthesis and eEF2 down-regulation is unclear.  
Our data supports the view that the intracellular actions of BTYNB are based on its 
ability to inhibit IMP-1. BTYNB exhibits similar dose response curves for inhibition of binding 
of IMP-1 to flMyc in vitro and for inhibition of cell proliferation. BTYNB inhibits proliferation 
of IMP-1 positive cells in which IMP-1 knockdown similarly inhibits cell proliferation and has 
no effect in IMP-1 negative cells in which IMP-1 siRNA has no effect. Overexpression of IMP-1 
abolishes BTYNB inhibition of cell proliferation. We also found that the BTNYB derivative, 
Compound 5226752, did not inhibit binding of IMP-1 to flMyc in vitro and did not downregulate 
IMP-1 mRNA targets c-Myc, Col5A, eEF2, CALM1, and TRCP1 in IMP-1 positive cells. 
Similarly, BTYNB did not down-regulate c-Myc, Col5A, eEF2, CALM1, and TRCP1 mRNAs 
in IMP-1 negative BG-1 cells (data not shown). 
Here we describe a broadly applicable HTS system for identifying small molecules that 
inhibit interaction of RNA-binding proteins with their RNA recognition sequences, demonstrate 
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that a small molecule identified using this simple in vitro assay with isolated components 
destabilizes c-Myc mRNA in cells, leading to decreases in steady state c-Myc mRNA and 
protein levels. Moreover, the small molecule identified using this system is broadly effective 
against diverse targets of the mRNA binding protein. BTYNB’s selectivity and low toxicity, 
effectiveness against diverse cancer-related IMP-1 mRNA targets, and ability to abolish 
anchorage independent growth of IMP-1 containing cancer cells make it a strong candidate for 
further therapeutic testing and development.  
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FIGURES 
             
 
 
 
 
 
 
Figure 3.1. Scheme for identification and characterization of small molecule inhibitors of 
IMP-1.  Our strategy for identification of small molecule IMP-1 inhibitors included the 
following assays. In vitro FAMA assays using purified IMP-1 and progesterone receptor 
(PR) and fluorescein-labeled c-Myc RNA and progesterone response element (PRE) to 
carry out the high throughput screen, verify the hits, and to further characterize the 
verified hits for potency, efficacy, and specificity. Cell growth assays for evaluating the 
ability of the lead small molecule candidates to inhibit proliferation of IMP-1 positive cells 
and testing for specificity and off-target toxicity in IMP-1-negative cancer cells.  Dose–
response studies of lead inhibitors to determine potency for inhibiting cell proliferation and 
early studies of mechanism of action.   
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Figure 3.2. Dose-response studies show BTYNB is a sequence and structure selective 
inhibitor of IMP-1 binding to flMyc. (A) Shown are structures of 2-{[(5-bromo-2-
thienyl)methylene] amino}benzamide (BTYNB) and Compound 5226752, a close structural 
relative of BTYNB.  Dose-response studies of the effect of BTYNB (B) and Compound 
5226752 (C) on binding of IMP-1 to flMyc and flPRE. 1 nM flMyc and 10 nM IMP-1 or 1 
nM flPRE and 30 nM PR-b and the indicated concentration of BTYNB (B) or Compound 
5226752 (C), were incubated and mA measured. No inhibitor control was set to 100%. 
(n=5, average  S.E.M. Some error bars are smaller than the symbols). 
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Figure 3.3. Structural relatives of BTYNB have little or no ability to inhibit binding of 
IMP-1 to flMyc. (A-G) Shown are structures of structural derivatives of BTYNB and dose 
response studies evaluating the ability of the compounds to inhibit binding of IMP-1 to 
flMyc. 1 nM flMyc and 10 nM IMP-1 and the indicated concentration of compound were 
incubated and mA measured. No inhibitor control was set to 100%. (n=5, average  
S.E.M). 
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Figure 3.4.  IMP-1/IGF2BP1/CRD-BP protein expression in 31 cancer cell lines. For 
Western blots, 20 g of protein lysate was loaded in each well and probed with IMP-1 
antibody as described in “Materials and Methods”.  Actin was used as a loading control.  
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Figure 3.5.  BTYNB decreases IMP-1 levels.   IMP-1 positive cell lines, (A) IGROV-1 and 
(B) SK-MEL2 cells were maintained as described in “Materials and Methods” and were 
treated with the indicated concentration of BTYNB for 72 hours, harvested, and analyzed 
by Western blot using 20 μg of protein/lane with tubulin as the internal standard.  
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Figure 3.6.  BTYNB decreases expression of IMP-1 mRNA targets. IMP-1 positive (A) 
IGROV-1 and (B) SK-MEL2 cells were maintained as described under “Materials and 
Methods” and were treated with either DMSO vehicle control or 10 μM of BTYNB for 72 
hours, harvested, and mRNA levels quantitated by qRTPCR. 36B4 was used as the internal 
standard. Data represents the mean ± S.E.M. for three separate experiments. *P<0.05. 
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Figure 3.7.  Knockdown of IMP-1 and treatment with BTYNB decrease expression of eEF2. 
Treatment with 10 μM BTYNB for 72 hours leads to a decrease in eEF2 mRNA in IGROV-
1 (A) and SK-MEL2 (B) cells. Treatment with 10 μM BTYNB for 72 hours lead to a 
decrease in eEF2 protein in IGROV-1 cells (C).  Treatment with 10 μM BTYNB for 24 
hours results in a decrease in protein synthesis in SK-MEL2 cells compared to cells treated 
with DMSO vehicle control (D).  Knockdown of IMP-1 in IGROV-1 cells leads to a 
decrease in IMP-1 (E) and (F) eEF2 mRNAs compared to cells treated with a non-coding 
(NC) control siRNA for 72 hours. (G) RNAi knockdown of IMP-1 for 72 hours in IGROV-1 
cells leads to a decrease in eEF2 protein.  qRTPCR data represents the mean ± S.E.M. for 
three separate experiments. The protein synthesis experiments shows the mean ± S.E.M. 
(n=4) *P<0.05, **P<0.01, ***P<0.001.  
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Figure 3.8.  BTYNB decreases the stability of c-Myc mRNA, reducing expression of c-Myc 
mRNA and protein.   (A) Decay of c-Myc mRNA was monitored in SK-MEL2 cells pre-
treated with either DMSO or 10 µM BTYNB and then treated with Actinomycin-D for the 
indicated times. c-Myc mRNA levels were determined by qRT-PCR using 36B4 as internal 
standard. The difference between 10 M BTYNB and the control (DMSO) was not 
significant (p >0.05) at 30 minutes, while the difference between 10 M BTYNB and the 
control (DMSO) at 1 hour was significant (p<0.05).  (B) SK-MEL2 cells were incubated 
with either DMSO or with 10 µM BTYNB for 72 hours and c-Myc mRNA was quantitated 
using qRT-PCR (C) c-Myc mRNA levels are reduced in SK-MEL2 cells treated for 72 
hours with IMP-1 siRNA compared to Non-coding (NC) control.  (D) Western blots 
showing a dose-response study of the effect of BTYNB on levels of c- Myc protein. Tubulin 
was used as a loading control. (A-C)  (n=3, avg + S.E.M.).  
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Figure 3.9.  IMP-1 knockdown blocks proliferation of IMP-1 positive cells with no effect in 
IMP-1 negative cells.  1,000 ES-2 (A), IGROV-1 (B), SK-MEL2 (C), BG-1 (D) or 
T47DKBluc (E) cells were initially plated.  Cells were then transfected with either 
noncoding (NC) control or IMP-1 siRNA and cell number was determined by MTS assay 5 
days later.  In all experiments, cell numbers were calculated from standard curves of cell 
number versus absorbance for each cell line and results are reported as the mean ± S.E.M. 
(n=5) n.s.=not significant, *P<0.05, **P<0.01, ***P<0.001.  
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Figure 3.10.  BTYNB is a dose-dependent inhibitor of IMP-1 positive cancer cell 
proliferation. 1,000 IMP-1 positive ES-2 (A), IGROV-1 (B), SK-MEL2 (C), or 1,000 IMP-1 
negative BG-1 (D) or T47DKBluc (E) cells were plated and treated with the indicated 
concentration of BTYNB. The dot represents the cell number (1,000 cells) at day 0. Cell 
number was assayed using MTS 3 days later (n=6, avg ± S.E.M.). IC50 values were obtained 
by curve-fitting using SigmaPlot.  
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Figure 3.11. Compound 5226752, a structural relative of BTYNB, does not inhibit 
proliferation of IMP-1 positive or IMP-1 negative cells.  1,000 ES-2 (A), IGROV-1 (B), SK-
MEL2 (C), BG-1 (D) or T47DKBluc (E) cells were initially plated and treated with the 
indicated concentrations of compound 5226752.  Cell number was assayed using MTS 3 
days later (n=6, avg ± S.E.M.). (F) BTYNB does not inhibit E2-ERα mediated gene 
expression.  To deplete endogenous estrogens, T47DKBluc cells that are stably transfected 
with an ERE luciferase reporter, were maintained in medium containing 10% charcoal-
dextran (CD) treated FBS for 4 days.  Cells were then maintained for 24 hours in medium 
without estrogen (white bar) or treated with estrogen (E2) and the indicated concentration 
of BTYNB (black bars). Cells were lysed and assayed for luciferase activity as we described 
(88). Results are reported as the mean ± S.E.M. (n=6). 
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Figure 3.12. Overexpression of IMP-1 reverses BTYNB inhibition of cell proliferation.  
HEK 293T cells were transiently transfected without IMP-1 expression plasmid (Control) 
or with 100 ng of CMV-IMP-1 expression plasmid (IMP-1 overexpression).  Western blot 
analysis demonstrates increased IMP-1 protein in the cells transfected with CMV-IMP-1 
(A).  1,000 HEK 293T cells were initially plated and either not transfected (B), transfected 
with a control plasmid (C), or transfected with the CMV-IMP-1 (IMP-1 overexpression) 
(D).  Cells were then treated with DMSO or 10 µM of BTYNB for 48 hours and assayed 
using MTS.  The difference between 10 M BTYNB and the control (DMSO) was 
significant in HEK 293T that were either not transfected or transfected with a control 
plasmid.  Cells that were transfected with an IMP-1 overexpression plasmid and treated 
with 10 M BTYNB and the control (DMSO) did not exhibit significant BTYNB inhibition 
of cell proliferation.  Results are reported as the mean ± S.E.M. (n=3)  n.s.=not significant, 
*P<0.05, **P<0.01, ***P<0.001.  
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Figure 3.13.  BTYNB inhibits anchorage-independent growth of IMP-1 positive cells in soft 
agar.  10,000 SK-MEL2 were plated into top agar containing  DMSO (vehicle) (A) or 10 
µM BTYNB (B).  8,000 ES-2 cells were plated into top agar containing  DMSO (vehicle) (C) 
or 10 µM BTYNB (D).  After 21 or 14 days for SK-MEL2 or ES-2 cells, respectively, 
colonies were counted and photographed at 10X magnification. The white scale bar in the 
photographs represents 10 µm.  The bar graphs represent the average of the total number 
of colonies counted in each well of the treatments for SK-MEL2 (E) or ES-2 (F) cells. The 
photographs are representative of the entire plate and of triplicate experiments. 
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CHAPTER 4 
IMP-1 Regulates Protein Kinase C alpha mRNA and protein Levels 
 
ABSTRACT 
 
PKCα (protein kinase C alpha, PRKCA) is an important protein involved in multiple 
signaling pathways in cancer, and Insulin Like Growth Factor 2 mRNA Binding Protein 1 
(IGF2BP1/IMP-1) has also been shown to participate in carcinogenesis. However, whether 
there is an interplay between PKCα and IMP-1 was unclear..  In this report we aimed to 
identify whether PKCα is a novel molecular target of IMP-1 and to study the likely 
biological impact of such an interaction.   Using bioinformatics analysis, we predicted 
PKCα mRNA levels were regulated by IMP-1 knockdown. We experimentally validated 
IMP-1 as a direct regulator of PKCα mRNA levels.  We also demonstrated that the 
targeting of PKCα by IMP-1 knockdown played a critical role in regulating downstream 
ERK signaling in cancer cells.  Consistent with IMP-1 stabilizing PKCα mRNA resulting in 
increased levels of PKCα mRNA and protein, transient overexpression of IMP-1 increase 
the level of PKCα protein. In summary, this study identifies IMP-1 as a novel protein that 
regulates PKCα and illustrates that the downregulation of PKCα by IMP-1 knockdown 
modulates ERK signaling, an important biological processes in cancer cells. 
 
INTRODUCTION 
 
Protein kinase C alpha (PKCα) is a serine/threonine kinase that plays a key role in several 
signal transduction pathways, including those involved in apoptosis,  cell proliferation and 
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migration (89-92).  The PKC family contains related isoforms with different cofactor 
requirements, tissue and subcellular distribution, and substrate specificity (93).  Based on their 
structural and functional characteristics, this protein family can be further classified into three 
subfamilies: conventional or classic PKC isozymes (cPKCs; α, βI, βII, and γ), novel or non-
classic PKC isozymes (nPKCs; δ, ε, η, and θ), and atypical PKC isozymes (aPKCs; ζ, ι, and λ). 
PKCα is known to play a role in cellular proliferation, apoptosis and the migration in many types 
of cancer including melanoma, breast, ovarian, and lung cancer (92, 94-96), making this protein 
an important therapeutic target in cancer (97).   
 microRNAs (miRNAs) are small ~22-nucleotide non-coding RNAs that are an 
important class of gene regulators that are present in both plant and animal genomes  (98, 99).  
Mature miRNAs incorporated into the RNA-induced silencing complex (RISC) regulate target 
mRNAs via complementary base pairing in the 3’UTR, 5’UTR, and protein coding regions (20). 
Binding of a miRNA-containing RISC to its target induces translational repression and/or mRNA 
degradation, thereby regulating target protein expression.   Evidence demonstrates miRNAs are 
critically involved in cancer biology, playing both tumor suppressor and oncogenic roles (100-
102).   Although it is estimated that approximately 60% of all human mRNAs are subject to 
miRNA-dependent regulation (103, 104) and numerous studies demonstrate the importance of 
miRNA-dependent regulation in vitro and in vivo (98), the function of each individual miRNA 
remains to be elucidated, particularly as it pertains to the development and progression of human 
cancers. 
 Insulin-like growth factor II mRNA binding protein (IGF2BP1/IMP1), also known as 
zipcode-binding protein 1 (ZBP1), is a member of the VICKZ (Vg1RBP/Vera, IMP-1,2,3, CRD-
BP, KOC and ZBP-1) family of RNA binding proteins (5).  IMP1 and its orthologs modulate 
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cellular functions by mediating many aspects of RNA regulation, including intracellular RNA 
localization, stability, and translational control (10, 34, 39).   As a largely oncofetal protein, 
IMP-1 binds to and stabilizes transcripts that are important in oncogenesis (18, 19, 60).  
Although IMP-1 has been reported to regulate the RNA stability of c-Myc (34), MDR1 (18), and 
TRCP-1(19, 20), and other oncogenes, we were interested in identifying whether or not there 
are novel molecular targets of IMP-1. IMP-1 was also previously found to attenuate miRNA-
dependent degradation of several mRNAs (20,44), including miR-340 mediated degradation of 
microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte 
development and melanogenesis.  Using miRWalk (105), miR-340 was the top miRNA predicted 
to bind to the 3’UTR of PKCɑ.   These miR-340 binding sites also contained IMP-1 binding 
motifs (UUUAY) (44,66), suggesting a role for both IMP-1 and mir-340 in regulating PKCɑ 
levels. We also postulated that IMP1 regulates the post-translational fate of a variety of mRNA 
targets in IMP-1 positive cancer cell lines.  Through inhibition of IMP1 expression, abnormal 
regulation of the associated mRNAs could result in changes in cell behavior and/or phenotype.  
In the present study, we used bioinformatic analysis of publically available microarrays and 
identified a panel of genes that were potentially regulated by IMP-1.  We then performed RNAi 
knockdown of IMP-1 positive cells to test whether or not there was a decrease in levels of the 
mRNAs encoded by the panel of genes.  From these studies, PKCα emerged as a novel 
molecular target of IMP-1.  IMP-1 knockdown not only decreased the level of PKCα mRNA and 
protein, but also led to a decrease in protein levels of the downstream signaling molecules, ERK 
and p-ERK.  Interestingly, when IMP-1 was overexpressed in HEK 293T cells, PKCα levels also 
increased, further supporting the idea that IMP-1 regulates PKCα mRNA.  Finally, we used a 
miRNA inhibitor of miR-340 and observed an increase in PKCɑ protein levels, suggesting a role 
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for miR-340 in regulating PKCɑ.  This work for the first time establishes the role of the 
oncofetal protein IMP-1 in regulating levels of PKCα, an important target in cancer.  
 
MATERIALS AND METHODS  
 
 
Cell Culture 
 
Unless otherwise indicated, cells were maintained at 37 °C in 5% CO2 in growth medium 
containing 1% penicillin and streptomycin and fetal bovine serum (FBS) (Atlanta Biological, 
Atlanta, GA).  IMP-1 positive IGROV-1, SK-MEL2, and HEK 293T cells were used in cell-
based experiments.  Cells were maintained in the following culture media.  IGROV-1, SK-MEL-
2: RPMI-1640, supplemented with 10% FBS; HEK 293T: DMEM-F12 supplemented with 10% 
FBS. 
 
Plasmids and Oligonucleotides 
 
The IMP-1 mammalian expression plasmid was created as follows: The IMP-1 coding region 
was amplified by PCR with a pair of primers, 5’-CAGCTGGTACCATGAACAAGC TTT ACA 
TCG GCA AC and 5’-GTATTCTAGACCTCACTTCCTTCGTGCCTGGGCCTG. The PCR 
product was digested with Kpn I and Xba I, and then cloned into pCMV-hER (106) to generate 
pCMV-IMP-1.  The empty plasmid pTZ18U served as a negative control.   Plasmids were 
transfected into KEK 293T cells using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions.   Locked nucleic acid (LNA) anti-sense oligonucleotides for miR-
340 and a miR-control were purchased from Exiqon, Inc.    
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Transient Transfections 
For siRNA transient transfection, IGROV-1 and SK-MEL2 cells plated at 300,000 cells/well in 
6-well plates in RPMI-1640 containing 10% FBS. Medium was replaced the next day with fresh 
medium containing either a non-coding siRNA smartpool (Dharmacon) or IMP-1 specific siRNA 
smartpool. Lipofectamine 2000 or Dharmafect 1 transfection reagent was used for transient 
transfections.  HEK 293T cells were maintained in DMEM/F12 containing 10% FBS and 
antibiotics. One day before transfection, 0.15 million cells were seeded into each well of a 24-
well plate. 1 g total DNA (carrier PTZ18U plasmid DNA was used to reach 1 g) was 
transfected into each well of a 24-well plate. Transfection using Lipofectamine 2000 was as 
described by the supplier (Invitrogen). Transfections used a ratio of DNA to Lipofectamine 2000 
of 1:3 with the cells in 0.5 ml Opti-MEM. 7-8 hours after transfection, the transfection medium 
was replaced with standard growth medium (DMEM/F12 plus 10% FBS and antibiotics). For 
transient transfections using the LNA miR inhibitors, IGROV-1 cells were seeded at a density of 
100,000 cells/well in 12 well plates.  The next day, after cells were allowed to adhere, LNA 
inhibitors were added to cells using Lipofectamine 2000 according to the manufacturer’s 
instructions.  The transfection complex was removed after 24 hours and replaced with complete 
medium.  After another 72 hours, cells were harvested and protein was extracted and analyzed 
using Western blot.   
 
Endogenous Gene Expression 
IGROV-1 and SK-MEL2 cells were plated and transiently transfected as described above.  
After 72 hours, RNA was extracted, and purified using the Qiagen RNeasy kit.  cDNA was 
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prepared from 1 μg of RNA with M-MuLV reverse transcriptase from New England Biolabs. 
Diluted cDNA was used to perform quantitative RT-PCR using SYBR Green (ABI 
Thermocycler).  Primers for quantitative RT-PCR were: 36B4 forward primer (5′-
GTGTTCGACAATGGCAGCAT) and reverse (5′-GACACCCTCCAGGAAGCGA); IMP-1 
forward primer (5’-TGAACACCGAGAGTGAGACG-3’) and reverse primer (5’-CTCATCG-
GGGATGTAGGAGA-3’); PRKCA forward primer (5’-ATGTCACAGTACGAGATGCAAAA) 
and reverse (5’-GCTTTCATTCTTGGGATCAGGAA).  The fold change in expression of each 
gene was calculated using the ΔΔCt method with 36B4 as the internal control. 
 
Whole Cell Extracts and Western Blots 
Following treatment, cells were harvested, washed in ice-cold phosphate-buffered saline (PBS), 
and whole-cell extracts were prepared in lysis buffer containing 1X radioimmunoprecipitation 
assay (RIPA) buffer (Millipore), 1 mM EGTA, 30 mM NaF, 2.5 mM sodium pyrophosphate, 1 
mM sodium orthovanadate, 1 mM β-glycerol phosphate, 1 mM phenylmethylsulfonyl fluoride, 
and 1 tablet of protease inhibitor cocktail (Roche, Indianapolis, IN). Cells were collected, and 
debris was pelleted by centrifugation at 15,000 g for 10 minutes at 4°C. The supernatants were 
collected and stored at −20°C. Then, 20 µg total protein was loaded onto 10% (v/v) sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels, separated, and transferred 
to nitrocellulose (GE Healthcare). IMP-1 protein was detected using IMP-1 antibody (sc-21026, 
Santa Cruz, CA), PKCɑ was detected using sc-208 (Santa Cruz) ERK was detected using 4695 
(Cell Signaling Technology), p-ERK was detected using 4370 (Cell Signaling Technology) and 
ɑ-tubulin, an internal standard was detected using antibody A1978 (Sigma). 
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Luciferase assays 
IGROV-1 cells were plated in complete medium (10% FBS + RPMI) at a concentration of 
20,000 cells/well in a 12 well plate.  After cells were allowed to adhere overnight, cells were 
transiently transfected with either a control non coding siRNA SMARTpool or and IMP-1-
specific siRNA SMARTpool as described above.  The transfection complex was removed and 
replaced with complete medium for an additional day.  The following day the cells were 
transiently transfected with a reporter containing 5 copies of an NF-B binding site driving expression 
of luciferase (NF-B)5-Luc (generous gift provided by Dr. Lin Feng Chen). 48 hours later, cells were 
washed once in phosphate-buffered saline, and 150 μl of 1× Passive Lysis Buffer (Promega, 
Madison, WI) was used to lyse the cells. Luciferase activity was determined using firefly 
luciferase reagent from Promega. 
Statistical Analysis 
Results are expressed as the mean ± S.E.M. of at least three independent experiments. 
Significance was established when p < 0.05. Student's t test was used for comparison of the 
means between two groups.  
RESULTS 
Identification of Downregulated Transcripts in IMP-1‐depleted HEK 293T Cells 
In order to identify novel molecular targets of IMP-1, we performed in silico analysis using 
publically available microarrays (65) in which IMP-1 had been depleted.  These studies had been 
initially conducted in the context of performing a transcriptome-wide analysis of proposed 
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binding sites for RNA-binding proteins including IMP-1. RNAi knockdown of IMP-1 in HEK 
293T cells confirmed decreases in IMP-1 regulated genes, but also revealed potential novel IMP-
1 regulated genes.  We were particularly interested in genes that are known to play a role in 
cancer, specifically in the processes of cell proliferation and migration.  A summary of lead 
candidates from the initial in silico analysis is presented in Table 4.1. 
 
Knockdown of IMP-1 Leads to a Decrease in PKC alpha mRNA 
Having established a set of potential novel IMP-1 regulated genes, we next wanted to see 
whether RNAi knockdown of IMP-1 in IMP-1 positive cancer cells could downregulate the 
expression of these genes.  In particular, we were interested in further exploring whether or not 
there was a decrease in genes related to cell proliferation, given that this is an important 
physiological readout of IMP-1 activity.  We observed a robust knockdown of IMP-1 in both 
IGROV-1 and SK-MEL2 cells (Figure 4.1A, 4.1C), and saw a decrease in PKCα mRNA 
(Figure 4.1B, 4.1D). Importantly, PKCα has been implicated in promoting proliferation in a 
variety of cancers, which is summarized in Table 4.2.  Interestingly, we were not able to see a 
decrease in Cyclin D2, (CCND2), which may suggest that either Cyclin D2 is not a molecular 
target of IMP-1, or its targeting by IMP-1 may be sell-specific.   
 
Knockdown of IMP-1 Leads to a Decrease in PKCα and ERK Protein 
 
In cancer cells, PKCα is involved in cell proliferation, survival, invasion, migration, apoptosis, 
and anticancer drug resistance through interaction with several signal transduction pathways (93, 
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107). For example, during cancer cell proliferation and survival, PKCα stimulates survival or 
proliferation-associated signaling pathways, such as Ras/Raf/MEK/ERK (108, 109) or PI3K/Akt 
(110)  pathways, but suppress the expression of cancer suppressor-associated or apoptotic signals 
such as the caspase cascade or Bax subfamily (111).  Given that ERK signaling is a well-known, 
downstream readout for PKCα activity, we were curious whether knockdown of IMP-1 could 
reduce ERK signaling via PKCα.  As shown in Figure 4.2, IMP-1 knockdown in IGROV-1 and 
SKMEL-2 cells led to a decrease in PKCα protein as well as basal ERK 1/2 and phosphorylated 
ERK 1/2 protein, suggesting the MAPK signaling pathway is altered upon IMP-1 depletion.   
 
Knockdown of IMP-1 Decreases PKCα Protein and Overexpression of IMP-1 Increases PKCα 
Protein in HEK 293T Cells 
As further confirmation of the results from the in silico microarray analysis where we observed a 
4 fold decrease in IMP-1 mRNA in HEK 293T cells that were depleted of IMP-1, knockdown of 
IMP-1 lead to a decrease in IMP-1 protein in the same cell line (Fig. 4.3A).  Knockdown of 
IMP-1 also lead to a decrease in PKCα protein (Fig 4.3A), which is consistent with the results 
we obtained for the IMP-1 positive cancer cell lines.  Interestingly, when we performed a 
transient transfection using either a control plasmid or an IMP-1 expression plasmid, the HEK 
293T cells in which IMP-1 was overexpressed also resulted in an increase in PKCα protein (Fig. 
4.3B), supporting the view that IMP-1 regulates PKCα levels. 
 
PKCα is Characterized as a Target for miR-340 
MicroRNAs (miRs) inhibit gene expression by binding to the mRNA transcript of the target gene 
to induce its degradation. To identify miRs that target PKCα, and might have some interplay 
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with IMP-1 in regulating PKCα levels we used four cited algorithms, miRanda – mirSVR, 
miRDB, miRWalk, and Targetscan, and identified miR-340 as a top predicted microRNA (Table 
4.3).   Three putative binding sites of the microRNA in the 3′-UTR of PKCα, with the IMP-1 binding 
sites overlaid are shown in Figure 4.4.  Given these in silico results, we then performed a 
transient transfection using a miR-340 antagonist and found that treatment with the mir-340 
inhibitor lead to an increase in PKCα protein as shown in Figure 4.5, suggesting a role of miR-
340 in regulating PKCα in cancer cells. 
 
DISCUSSION 
As the importance of IMP-1 in cancer is being elucidated, it is critical to fully understand the 
functions of this oncofetal RNA-binding protein related to the development and progression of 
the disease.  IMP-1 has classically been recognized for its ability to regulate mRNAs by 
modulating their stability and translation (5).  However, the effect of IMP-1 on each mRNA 
target is usually modest, making it challenging to explain the pathophysiological effects of IMP-
1 through its regulation of a single target (6).  Despite this, it is important to identify novel 
molecular targets of IMP-1 and relate these to cancer pathology in order expand our knowledge 
of the complex regulatory networks influenced by IMP-1.  In this report, we demonstrate that 
IMP-1 regulates the level of PKCα in ovarian and melanoma cells, and has downstream effects 
on the RAS–RAF–MAPK pathway by altering ERK 1/2 levels.  We also show that miR-340, 
which has been previously shown to work in conjunction with IMP-1 to regulate the 
microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte development 
and melanogenesis, as regulating PKCα protein levels.   Using miRWalk and other tools for predicted 
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micro RNA (miR) binding sites in the  PKCα mRNA 3’-UTR (105), miR-340 was the top miR (Table 3). 
This lends additional support to the idea that PKCα is a molecular target for IMP-1.  One potential 
mechanism by which IMP-1 might increase PKCα levels is by binding to the IMP-1 binding sequence 
motif (UUUAY), which has previously been identified in Drosophila (66) and is found in the 3’-UTR of 
PKCα mRNA (Figure 4.4).  A future direction of this research will involve further exploring the interplay 
between IMP-1 and mir-340 in regulating PKCα levels.   
 In addition to enhancing cell proliferation, PKCα has been implicated in promoting 
inflammation and preventing apoptosis of cancer cells (112-114). Importantly, activation of 
PKCα has been linked to NF-B activation and induction of inhibitor of apoptosis (IAP) genes, 
including IAP1, IAP2, X-IAP, and survivin (115).  We and others have shown that RNAi 
knockdown of IMP-1 leads to reduced expression of an NF-B luciferase reporter (19) (Fig. 
4.6).  Interestingly from in silico analysis we identified 4 potential NF-B binding sites in the 
IMP-1 promoter region (nt -2000—+1), suggesting that in addition to being activated 
downstream of PKCα, NF-B may directly act as a transcription factor for IMP-1.  Taken 
together, this suggests that there may exist a pro-inflammatory, positive feedback regulatory loop 
in which IMP-1 increases NF-B activity and NF-B induces additional IMP-1. 
 Although our findings support previous research regarding the oncogenic activity of 
IMP-1 in cancer, our data also highlight PKCα as a novel molecular target of IMP-1 in cancer 
and explores the effect of IMP-1 knockdown on the RAS–RAF–MAPK signal transduction 
pathway in ovarian cancer and melanoma.  Future studies that explore regulatory mechanisms 
relating IMP-1 and PKCα expression, including miRNA regulatory networks and NF-B activity 
will provide greater understanding of IMP-1 in cancer biology and may represent new avenues 
for therapeutic interventions to improve the prognosis of IMP-1 positive cancers. 
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TABLES 
Table 4.1—Downregulated transcripts in IMP-1—depleted HEK 293T cells from 
microarray analysis 
Gene Function Fold Change 
JKAMP Regulator of the duration of MAPK8 activity in response to various 
stress stimuli. Facilitates degradation of misfolded endoplasmic 
reticulum (ER) luminal proteins through the recruitment of 
components of the proteasome and endoplasmic reticulum-associated 
degradation (ERAD) system.    
-3.91 
 
PRKCA Calcium-activated, phospholipid- and diacylglycerol (DAG)-
dependent serine/ threonine-protein kinase that is involved in 
regulation of cell proliferation, apoptosis, differentiation, migration 
and adhesion, tumorigenesis  by directly phosphorylating targets such 
as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling 
cascade involving MAPK1/3 (ERK1/2) and RAP1GAP.  
-2.35 
 
CCND2 Member of the cyclin protein family that is involved in regulating cell 
cycle progression.  
-2.18 
NUDT21 Component of the cleavage factor Im (CFIm) complex that plays a 
key role in pre-mRNA 3'-processing.   
-3.80 
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Table 4.2—PKCα and its roles in multiple types of cancer cells 
 
Cancer Role in Cancer Reference 
Breast cancer Cell proliferation and 
metastasis, antiapoptosis, 
antiestrogen resistance 
(116-118) 
Ovarian cancer Cell proliferation and invasion (119,120) 
Melanoma Cell survival, invasion, and 
migration 
(94,121) 
Lung cancer Cell proliferation, metastasis, 
and antiapoptosis 
(92,122) 
Liver cancer Cell growth, invasion, and 
migration 
(108,109) 
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Table 4.3—Predicted miRNA sites on PRKCA mRNA 3' UTR region produced by 
miRWalk and other programs  
microRNA miRanda miRDB miRWalk 
  
RNA22 Targetscan 
hsa-miR-340 X X X X X 
hsa-miR-514 X X X  X 
hsa-mir-370 X  X X X 
hsa-miR-432 X  X X X 
hsa-miR-205 X X X  X 
hsa-miR-424 X  X X X 
hsa-miR-1827 X  X X X 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Knockdown of IMP-1 decreases PKCα mRNA.  IGROV-1 and SKMEL-2 cells 
were treated with Noncoding Control (NC) or IMP-1 siRNA for 72 hours before RNA 
extraction. IMP-1 (A, C) and PKCα (B,D) mRNA was quantitated using quantitative RT-
PCR and normalized to 36B4. Data represent the mean of three independent experiments 
±S.E.M. 
 
 
 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.  Knockdown of IMP-1 decreases PKCα and ERK protein.   IGROV-1 (A) and 
SKMEL-2 (B) cells were treated with Noncoding Control (NC) or IMP-1 siRNA for 72 
hours before the cells were harvested, protein was extracted, and equal amounts of protein 
were fractionated on 10% polyacrylamide gels and analyzed by Western blotting.  Tubulin 
served as a loading control.  
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Figure 4.3.  Knockdown of IMP-1 leads to a decrease in PKCα protein while 
overexpression of IMP-1 leads to an increase in PKCα protein in HEK 293T cells. HEK 
293T cells were either treated with scramble shRNA or IMP-1 shRNA for 72 hours (A) or 
transfected with a control plasmid or an IMP-1 overexpression plasmid for 48 hours (B).  
In both A and B, 20 µg of protein lysate was loaded and blots were probed for IMP-1, 
PKCα, and α-tubulin as a loading control.   
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Putative site 1 
        nt 3291 
 
 
Putative site 2 
                           nt 3371 
PRKCA 3’UTR—5’..AGUAUAAA GAGAGUAUUAUAAUUUUAUAAG ACACAAU 
                                      
 
Putative site 3 
   nt 8111 
PRKCA 3’UTR—5’..CAGAAAAUAGGUGUCAAGUCCACUUUAUAAGAACCUUUUU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Putative binding sites for miR-340 and IMP-1 in the 3’UTR of PKCα mRNA.  3 
potential binding sites for miR-340 in the 3’ UTR of PKCα mRNA are indicated with pink 
boxes and IMP-1 binding sites are overlaid in green. 
 
 
 
 
PRKCA 3’UTR—5’.. AUGCAUCAUGCAAUGAAUUUUGCAUGUUUAUAAUAAACCU 
 98 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. miR-340 regulates PKCα protein levels.  IGROV-1 cells were plated in complete 
medium and then either transiently transfected with a control microRNA inhibitor or a 
miR-340 inhibitor.  Cells were harvested and protein was harvested an analyzed using 
Western blot analysis.  Tubulin served as a loading control.   
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Figure 4.6.  IMP-1 knock-down in IGROV-1 cells reduces NF-κB luciferase activity.    
IGROV-1 cells were transfected as follows: Day 0: Control (NC) or IMP siRNA; Day 2: 
(NF-B)5-luc; Day 4: Treatment with TNFα (10 ng/mL). Luciferase activity was assayed on 
day 5. (n= 3; avg  SEM). p<0.05. 
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CHAPTER 5 
DISCUSSION  
 
IGF2 mRNA-binding protein 1 (IGF2BP1/IMP-1) is a member of the RNA-binding 
IGF2BP protein family, which is also called the VICKZ proteins, which comprises three 
members in mammals (IMP-1/2/3) (5).  Several studies have shown that IMP-1controls the 
localization, translation and/or turnover of specific mRNAs such as c-Myc in the cytoplasm, and 
serves an essential function in modulating cell proliferation, and migration (6,15,27,52,123).  
The significance of IMP-1 action is emphasized by the fact that IMP-1 exhibits an oncofetal 
pattern of expression, meaning that it is expressed during development, largely turned off in non-
neoplastic adult tissue, and often re-expressed in cancer.  This RNA-binding protein is expressed 
in a diverse range of primary malignancies, including breast, ovarian, lung, skin, and colon 
cancer and in most other cancers.    Moreover, IMP-1 expression correlates with increased 
metastasis and overall poor prognosis, suggesting that IMP-1 is a critical oncogenic factor.   
Given its oncofetal pattern of expression, its role in a variety of cancers, and the fact that 
there are no known inhibitors of IMP-1, my research has focused on identifying and 
characterizing new small molecule inhibitors of IMP-1 action. These inhibitors could then serve 
as starting points for the development of therapeutically relevant drugs and additionally will be 
useful as probes to improve our understanding of IMP-1’s oncogenic activities.  As described in 
Chapter 2, we first performed a pilot screen to serve as proof of principle that our screening 
method was appropriate for identifying small molecule inhibitors of IMP-1.  Further, as detailed 
in Chapter 3, we performed a high throughput screen to help us identify applicable chemical 
scaffolds. This document elaborates on screening methodologies and mechanistic studies 
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performed to better understand the ‘lead’ compound identified in our studies.  In Chapter 4, we 
circle back to the role of IMP-1 in cancer etiology and report the identification of the well-known 
protein kinase, PKC as a novel molecular target of IMP-1. 
 
High throughput screening          
  
High throughput screening (HTS) is an automated process that allows the researcher to quickly 
assay the biological or biochemical activity of a large number of drug-like compounds once the 
steps required for implementation are designed; however, it requires a fair amount of initial 
groundwork before assembly into a fully feasible high throughput screen. Although our 
laboratory has extensive experience with designing both in vitro biochemical and cell-based 
screens, the screen for IMP-1 inhibitors was the first to use a long, single stranded RNA probe, 
there was no template to follow. Every step in the screen was carefully planned and executed on 
a pilot scale before the actual screen. There were quite a few challenging hurdles before each 
segment of the screen was set up.   For example, in order to test compounds in a high throughput 
screen for their ability to inhibit binding of IMP-1 to a 93 nucleotide fluorescein-labeled c-Myc 
RNA binding site (flMyc), we had to synthesize milligram amounts of IMP-1 and the RNA 
probe.  In order to obtain biologically active IMP-1, we modified a purification protocol that 
utilizes an expression system for recombinant untagged IMP-1 using E. coli stably expressing 
several rare tRNAs. The IMP-1 produced using this more labor intensive protocol was at least 
100 fold more active than His-tagged IMP-1 we used in a study several years ago.   Additionally, 
because the 93 nucleotide c-Myc RNA binding site was too large to synthesize commercially, we 
developed simple methods for in vitro synthesis and fluorescein-labeling of the RNA. 
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 We carried out an initial pilot screen of 17,600 small molecules using in vitro 
fluorescence anisotropy microplate assay (FAMA).  Our aim was to demonstrate that this method 
could be used to identify small molecules that interfere with IMP-1 binding to c-Myc mRNA.  
Although this biochemical approach raises fewer technical concerns compared to cell-based 
screening with regard to off-target effects, we still wanted to exclude from our analyses 
compounds with intrinsic fluorescence, which could be regarded as false positives.  In order to 
address this, we developed a sequential protocol where we assessed changes in anisotropy, 
intrinsic fluorescence of test compounds, the compounds’ influence on the anisotropy signal of 
the probe alone, and the ability of compounds to inhibit binding of IMP-1 to flMyc.  The screen 
had a robust Z’-factor value of 0.6 which makes it a very reproducible assay and suitable for 
HTS.  
 Based on the results of the successful pilot screen we carried out a high throughput screen 
of ~ 150,000 small molecules from the University of Illinois High Throughput Screening Center.  
Using a similar set up as the pilot screen, we executed the primary high throughput screen. To 
increase the likelihood of identifying relatively potent medically relevant inhibitors, we screened 
using the relatively low concentration of 5μM of each compound. We developed and 
implemented a screening program to filter out hits and tier lead compounds based on 
characteristics such as potency and lack of intrinsic fluorescence.  Since our primary screen was 
for inhibition of binding of IMP-1 to flMyc, it did not exclude compounds that non-specifically 
denature proteins or alter their structure.  Therefore, we retested hits to test for specificity by 
evaluating their ability to inhibit binding of the steroid hormone receptor, progesterone receptor 
(PR), to its fluorescein-labeled DNA binding site (fl-progesterone response element; flPRE). We 
chose to retest hits for specificity using PR:fl-PRE FAMA, because this assay produces a similar 
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change in anisotropy as was observed for IMP-1 binding to c-Myc.  Because the PR:flPRE assay 
looks at inhibition of binding of a DNA binding protein to a DNA response element, this may 
also shed insight as to whether or not the hits identified from the screen were specific to 
inhibiting an RNA binding protein—RNA interaction.  In addition to the results from the 
PR:flPRE assays, we also had data for compounds identified for a previous FAMA screen that 
identified the estrogen receptor (ER) inhibitor TPSF.   Although the ER inhibitor screen was 
carried out using a different final concentration of compound, this also shed insight as to whether 
or not inhibitors from our screen were also identified from those studies and therefore most 
likely broadly toxic compounds.   
 Although many in vitro screens typically use an orthogonal in vitro assay such as 
electrophoretic mobility shift assay (EMSA) to further validate lead inhibitors, the assays do not 
address a clear bottleneck in drug discovery—the ability of a compound to recapitulate effects 
observed in biochemical assays in the complex environment of cells.  Therefore, we assessed 
how effectively and selectively the hits inhibited a key activity of IMP-1; stimulation of cell 
proliferation.  One of the challenges of this project was to establish accurate cell-based assays for 
IMP-1.  Unlike other systems such as estrogen receptor where there is an  extensive and well-
documented literature describing the presence or absence of ER in a particular cell line, IMP-1 is 
a relatively new molecular target in cancer biology and thus required initial groundwork to 
establish IMP-1 positive and negative cell lines for cell-based experiments.  To establish a cell-
based assay to filter the hits, we used RNAi knockdown of IMP-1 to confirm that IMP-1 
expression was essential for proliferation of IMP-1 positive cells and that IMP-1 RNAi 
knockdown had no effect on proliferation of IMP-1 negative cells.  The RNAi knockdown 
studies also helped verify that the antibodies we were using were specific for IMP-1. Using a 
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panel of IMP-1 positive and negative cells, we filtered compounds that inhibited proliferation of 
IMP-1 positive cells with little or no effect on IMP-1 negative cells.  Among this subset of 
compounds, we identified 2-{[(5-bromo-2-thienyl) methylene] amino} benzamide (BTYNB) as 
our lead inhibitor.   
 An alternative to high throughput screening is to identify hits using rational design or 
virtual screening. Both approaches require significant structural information that has not been 
fully elucidated for IMP-1.  Although the crystal structure for part of the chicken orthologue of 
IMP-1, ZBP-1, has been solved, it remains difficult to predict chemical scaffolds that could 
successfully inhibit IMP-1 function.  Thus, rational design and virtual screen are not presently 
feasible and HTS is a reasonable approach for identifying novel inhibitors of IMP-1.   
 
BTYNB—A promising new inhibitor of IMP-1 action 
Following the primary in vitro high throughput screen and follow-on cell-based assays, we 
identified 2-{[(5-bromo-2-thienyl) methylene] amino} benzamide (BTYNB) as our lead 
inhibitor.  BTYNB exhibited similar values for 50% inhibition of binding of IMP-1 to flMyc in 
vitro and for inhibition of proliferation of IMP-1 positive cancer cells.  BTYNB inhibited 
anchorage-independent growth of IMP-1 positive cells in soft agar.  Overexpression of IMP-1 
reversed BTYNB’s inhibition of cell proliferation, suggesting that the compound is acting 
through IMP-1.    Treatment with BTYNB decreased IMP-1 target mRNAs, such as eEF2 and 
CDC34 in IMP-1 positive cells, but had no effect on these mRNAs in IMP-1 negative cells. We 
show that BTYNB decreased stability of c-Myc mRNA at 1 hour and that treatment with 
BTYNB decreases steady state c-Myc mRNA and protein at 72 hours.  To our knowledge, this is 
the first small molecule inhibitor to decrease mRNA stability and the first small molecule 
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inhibitor of IMP-1, and important but previously untargeted protein in cancer.  We aspire to 
advance this promising IMP-1 inhibitor through preclinical studies.  Although discussed here, 
these long term goals are beyond the scope of this thesis.   
 
Lead optimization of BTYNB using limited structure-activity relationships (SAR) 
Eight commercially available structural analogues of BTYNB were evaluated as part of 
optimization studies.  One small molecule was able to inhibit binding of IMP-1 to flmyc in 
FAMA by 30% when tested at 10 µM; however, all of the other analogues of this chemical 
family did not inhibit binding.  When tested for inhibition of cell proliferation, this small 
molecule inhibited proliferation of IMP-1 negative cells, and thus was considered potentially 
toxic.  While limited, this structural data could serve as a guide for synthesis of BTYNB 
derivatives with improved potency and specificity.  Promising compounds that emerge from 
optimization can be evaluated for specificity using FAMA and cell proliferation studies using 
multiple IMP-1 positive and negative cell lines.  Ultimately, microarrays can test for off-target 
effects of BTYNB treatment.   
 
Identification of PKC as a novel molecular target of IMP-1 
 
In Chapter 4, I demonstrate that PKC expression levels are directly related to IMP-1expression 
levels by either overexpressing or decreasing IMP-1 levels in HEK 293T and cancer cell lines. I 
also used Western blot analysis to demonstrate that IMP-1 depletion decreases PKC and ERK 
protein levels, suggesting that IMP-1 regulates the RAS-RAF-MAPK signaling pathway.  Taken 
together, this data strongly suggest that PKC is a legitimate target of IMP-1.  Interestingly, 
using tools such as Target Scan and miRWALK, we found that the 3’-UTR of PKC mRNA 
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contains binding sites for both IMP-1 and miR-340.  miR-340 and IMP-1 have previously been 
shown to compete for binding to the 3’-UTR of MITF mRNA (44), lending further credence to 
the view that PKC is a molecular target of IMP-1.  Using a miR-340 inhibitor, we observed an 
increase in PKC protein levels, suggesting that PKC is regulated by miR-340.   This also 
highlights the possibility that miR-340 may be functioning in conjunction with IMP-1 to regulate 
PKC levels and future studies may focus on elucidating this complex regulatory network.   
 
Future studies to evaluate BTYNB in mouse xenograft models 
The in vivo effectiveness of BTYNB, or the lead compound to emerge from optimization, must 
be determined in preclinical animal models in order to establish its potential for use in human 
therapy.  This could be tested in IMP-1 positive ES-2 ovarian cancer and SK-MEL2 melanoma 
cell models because there is an unmet need for novel therapeutic agents in ovarian cancer and 
melanomas due to chemotherapy resistance, metastatic potential, and these cell lines exhibit stem 
cell-like properties. It has been widely proposed that residual stem cells repopulate tumors after 
therapy.   Initial tumor studies involve generating ES-2 and SK-EML2 mouse xenografts with 
bioluminescent imaging to visualize both the primary tumor and potential metastases.  Another 
future direction of this work will involve optimizing BTYNB by pharmacokinetics as well as 
determining the maximum tolerated dose and performing histopathologic assessment of tissues 
and organs from BTYNB-treated mice.     The results from these studies will be the basis for 
future studies determining whether potency, specificity, and toxicity can be improved with 
medicinal chemistry. 
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The ultimate goal of this research is to develop BTYNB so that it is suitable for further 
optimization and establish it as a potential therapeutic for IMP-1 positive cancers, for which 
there are few targeted therapies.   
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